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ABSTRACT 
Pneumonia is the second leading cause of disability-adjusted life-years 
lost worldwide and the eighth leading cause of death in the United States. 
Traumatic brain injury (TBI) patients have classically been considered 
immunosuppressed, but recent research reported that mild head trauma patients 
have reduced incidence of pneumonia compared to blunt trauma patients. Using 
our mild TBI model followed by bacterial pneumonia, we investigated the effect of 
neuronal signaling on innate immune function. To test whether any mild injury 
primes host immune responses to pneumonia, we generated a mild tail trauma 
(TT) model. mTBI mice showed protection from bacterial pneumonia while TT 
mice did not. Using an FDA-approved neurokinin-1 receptor (NK1R) antagonist, 
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aprepitant, we confirmed our previous findings that substance P (SP) is a key 
mediator of enhanced resistance to pneumonia. 
Blocking NK1R showed that mTBI-induced release of SP augments 
pulmonary neutrophil recruitment and microbicidal activity to pulmonary bacterial 
pathogens. In TT mice, NK1R agonism enhanced the same neutrophil functions, 
further supporting the hypothesis. No differences were found between mTBI and 
TT neutrophils’ ability to phagocytose, generate oxidative burst, or acidify 
phagosomes. However, neutrophils from mTBI mice produced more neutrophil 
extracellular traps in response to bacterial challenge. These studies show that 
neurokinin signaling in our model contributes to enhanced bacterial clearance. 
Cholinergic anti-inflammatory pathway signaling though the α7 nicotinic 
acetylcholine receptor (α7 nAChR) is also a critical component of improved 
survival. Blockade of α7 nAChR abrogated the mTBI survival benefit. Mimicking 
cholinergic signaling using α7 nAChR agonist recapitulated the mTBI reduced 
pro-inflammatory cytokine production and improved survival. No physiologic 
differences emerged within 24h following pneumonia, but mTBI and α7 agonist 
treated mice had significantly lower TNFα in bronchoalveolar fluid, suggesting 
reduced injurious pulmonary inflammation. However, replacing early TNFα during 
pneumonia did not increase mortality. Western blot analysis showed 
downregulation of HMGB1 release in mTBI mice, suggesting that vagal 
cholinergic signaling reduces late mediators of organ damage.  
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Our experiments show that mTBI enhances resistance to pneumonia by 
activating the vagus nerve signaling through neurokinin and cholinergic 
pathways. Translation of these findings could be innovative solutions to fighting 
or preventing infections.  
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Chapter 1: Introduction 
 
Traumatic Brain Injuries 
Traumatic Brain Injuries (TBIs) are caused by an external blow or penetrating 
head injury that alters normal brain functions. In the United States, approximately 
2.5 million TBI-related emergency department visits, hospitalizations, or deaths 
occur each year (26). TBIs are categorized as mild, moderate, or severe 
depending on the duration of loss of consciousness, post-traumatic amnesia, and 
neurological deficits. The most common method to determine neurological injury 
severity is the Glasgow Coma Scale (GCS). The GCS was first published in 1974 
by Teasdale and Jennett (186) to provide a standardized assessment and 
reporting of consciousness. Three factors were chosen to limit interobserver 
variability and reduce bias about the arousal level of patients. Evaluation of eye 
opening (1-4), verbal response (1-5), and motor response (1-6) provides a 
snapshot of the cognitive function as well as prognosis. The sum of these defines 
the severity of injury as mild (13-15), moderate (9-12), or severe (3-8), which was 
first subdivided in 1982 (157) with distinct differences in outcomes. The Medical 
Research Council Corticosteroid Randomization After Significant Head Injury 
(MRC CRASH) was the largest international, randomized control trial on 
traumatic brain injury totaling 10,008 patients (57, 159). CRASH trial data 
showed that GCS is inversely related to risk of death (35). The GCS score has 
been in use for more than forty years and still performs equally to newer models 
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in predicting outcomes following TBI (100). Neuroimaging is important after the 
injury to identify and localize any lesions, as many of them can lead to 
deleterious outcomes (113). Careful evaluation of the patient is critical as the 
etiology and pathophysiology of TBIs are heterogeneous.  
 
The pathophysiology of TBI is divided into two phases: primary and secondary 
injury. Primary injuries occur at the initial trauma, such as blunt or penetrating 
trauma, blast injuries, or rapid acceleration/deceleration of the skull (133). 
Common primary injuries are cerebral contusions and hemorrhage or 
hematomas following these insults. Damage to the vessels due to the movement 
of the brain or direct trauma causes intracranial bleeding. This results in 
hemorrhage or hematomas, either of which can cause mass effects due to the 
tight enclosure of the skull around the brain that lead to neurological damage. CT 
identification of these abnormalities can provide enhanced prognosis for patients 
(125). Contusions are direct injury of the brain parenchyma either at the spot of 
impact, termed “coup”, or on the opposing side, termed “contrecoup” (53, 149). 
Contusions are most commonly seen in the temporal and the ventral part of the 
frontal lobes because of the impact of the brain on the ridged skull floor (133). 
Rapid changes in the movement of the brain, such as repeated shaking or 
sudden deceleration, can cause shearing of axonal tracts that leads to diffuse 
axonal injury (DAI). Sudden changes in impulse transfer energy to the 
heterogeneous structure of the brain results in shear forces being generated. 
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These forces cause irreversible damage to cytoskeletal components of axons. 
DAI results in multiple focal lesions in discrete regions, usually the brainstem, 
parasagittal cortical white matter, and corpus callosum. DAI generally presents 
with loss of consciousness and often results in comas with poor prognosis (133).  
Neuroimaging is important to identify many of these injuries, especially 
those that require neurosurgical intervention. However, in mild TBIs, <10% who 
receive a CT scan have an abnormality detected and generally do not require 
intervention. Thus, head CTs are not recommended for mTBI patients unless 
presenting with several symptoms or risk factors such as headache, vomiting, 
>60y/o, intoxication, or focal neurological deficits.  Single photon emission 
computed tomography (SPECT) is another test useful for mTBI. SPECT has a 
high negative predictive value in mTBI patients and can be combined into 
SPECT/CT systems to provide better diagnoses. It requires radioactive tracers 
and no standardized guidelines for its use currently exist, thus limiting its use. A 
promising new modality is functional near-infrared spectroscopy (fNIRS), which 
detects laser scatter underneath tissue and reports cerebral blood flow akin to 
fMRI. fNIRS can detect only damage to the cortex, but this is sufficient to detect 
lesions in the prefrontal cortex, the area responsible for executive function. This 
technique could prove useful in quickly detecting or predicting alterations in 
executive function following mild TBIs (3). 
Primary injuries initiate secondary injury processes, which persist for 
hours to days that exacerbate neurological deficits. Inflammatory cascades, cell 
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death, and neural excitotoxicity can result in greater damage. Parenchymal 
damage can release damage associated molecular patterns (DAMPs) that 
activate the immune system and recruit immune cells. Recruitment of 
macrophages and neutrophils to the brain can further inflammation and 
contribute to additional injury (37). Excitotoxicity is mediated by extracellular 
glutamate levels, which are increased following TBIs by blood brain barrier (BBB) 
disruption, enhanced release, or impaired clearance. High concentrations of 
extracellular glutamate cause excessive activation of ionotropic glutamate 
receptors. These receptors allow unchecked calcium influx that indiscriminately 
activates calcium-dependent enzymes throughout the cells (211). Activation of 
calpains, Ca2+-dependent proteases, can cause cytoskeletal damage and cell 
death (99). Clark et al. showed that resected injured areas of brain from TBI 
patients had significantly more caspase-1 and -3 expression as well as cleavage 
products compared to post-mortem non-head trauma controls. Furthermore, TBI 
patients had many necrotic and apoptotic cells identified by terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining (33). 
Other pathways can also contribute to neuronal cell death. Using in vitro models 
of axonal stretch injury and a murine cortical impact model, apoptosis-inducing 
factor (AIF) translocates to the nucleus of neurons to induce cell death 
independent of caspase(s). SiRNA disruption in culture or mutant AIF mice 
showed reduced neuronal apoptosis following injury, thus linking AIF to cell death 
(173). The extent of cytoskeletal damage, extracellular milieu, or dysregulation of 
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proteins can all contribute to secondary cellular death after TBI through necrotic 
or apoptotic pathways (153). Currently, there are no effective treatments for 
secondary injury following TBI. 
 
TBIs, with increasing severity, can have drastic effects on neural signaling that 
classically result in behavioral changes, loss of consciousness, and memory loss. 
Neuroimmune signaling pathways can also be altered by head injuries. Three 
tracts have been implicated in alteration of innate immunity: (1) the hypothalamic-
pituitary-adrenal (HPA) axis, (2) the sympathetic nervous system, and (3) the 
vagus nerve (parasympathetic nervous system).  
 
HPA Axis 
The HPA axis can be activated by peripheral cytokine signaling, primarily 
interleukin-1β (IL-1β) or by TBIs themselves. TBI patients have been shown to 
have elevated levels of cortisol following injury (94, 102). Stimulating this 
pathway causes release of corticotrophin releasing hormone (CRH) by the 
hypothalamus, which in turn causes adrenocorticotropic hormone (ACTH) 
signaling to the adrenal cortex to release high levels of glucocorticoids. 
Glucocorticoids are known for their potent suppression of the immune system 
through increased anti-inflammatory cytokines IL-10 and TGF-β and decreased 
pro-inflammatory IL-1 and tumor necrosis factor α (TNFα). Glucocorticoids are 
known to inhibit innate immune cell functions. Early work by Jones et al. showed 
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that prednisolone treatment decreases neutrophil phagocytic functions (98). 
Thus, HPA-axis activation induces immunosuppression through glucocorticoid 
release. (206).  
 Corticosteroid administration had previously been shown to reduce 
intracranial pressure, which may be beneficial in head trauma patients. Early 
randomized controlled trials resulted in uncertainty about the use of 
corticosteroids following TBIs. Systematic reviews of randomized controlled trials 
could not produce a definitive conclusion (2). However, in a randomized 
controlled trial of 10,008 patients receiving either a 48h infusion of corticosteroid 
or placebo, the MRC CRASH trial reported a significantly higher risk of death 
within two weeks in the corticosteroid group (25.7% vs 22.3%) and a relative risk 
of 1.15 (57). Recent reports show that almost a quarter of moderate to severe 
TBI patients have HPA disturbances manifested by adrenal insufficiency, the 
inability to produce cortisol. Interestingly, adrenal insufficiency had no effect on 
outcome, potentially supporting that corticosteroid administration shows no 
benefit (121).  
 
Sympathetic Nervous System (SNS) 
The sympathetic nervous system (SNS), classically known for the “flight or fight” 
response, innervates multiple immune organs and its adrenergic receptors are 
expressed on circulating immune cells. This pathway has been shown to be 
activated following TBI characterized by elevated levels of norepinephrine, which 
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has been termed a “paroxysmal sympathetic storm” (34, 83). Dysfunction in 
central autonomic regions and adrenal medulla contribute to the excessive 
catecholamine release. In both patients and rats, brain injury induces rapid 
systemic IL-10 release from monocytes in a catecholamine β-adrenergic receptor 
dependent manner (205). In addition to IL-10 release, catecholamine signaling 
can also blunt production of pro-inflammatory cytokines and immune cell function 
(82). Despite this evidence of SNS-induced immunosuppression, treatment with 
β-adrenergic receptor blockers improved outcomes in severe TBI patients 
despite increased incidence of infections. Thus the autonomic dysfunction may 
overshadow the depression of immune function (39) following severe TBIs for 
overall outcome, but it presents evidence that SNS activation does induce 
immunosuppression.  
 
Parasympathetic Nervous System (PNS) 
PNS activity opposes the actions of the SNS, or better known as “rest and 
digest”. Its activity can be measured by heart rate variability (HRV), where the 
ratio of high frequency (HF) to low frequency (LF) is a measurement of balance 
between the PNS and SNS. Higher HF/LF HRV ratio indicates parasympathetic 
dominance and increased activity of the vagus nerve. Studies have shown this 
heightened vagal tone in TBI patients and patients who have increased 
intracranial pressure (ICP) (106). Early studies showed in cats that increases in 
ICP resulted in slower heart rates, indicating stimulation of PNS activity (129). 
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Overactivity of the vagus nerve is thought to induce immunosuppression through 
the downregulation of pro-inflammatory cytokine production mediated by the 
cholinergic anti-inflammatory reflex. Patients with head injuries exhibit reduced 
ex vivo production of TNFα correlated with increased HF signal power (109). 
Interestingly, patients with intracerebral trauma had significantly reduced 
production of TNFα than either TBI or stroke. Thus, vagal signaling intensity may 
depend on the type of injury. TBI induced hyperactivity of the vagus nerve is 
thought to contribute to the susceptibility to infections (77).  
 
Pneumonia 
Disease Burden  
Lower respiratory tract infections are the second leading cause of disability 
adjusted life-years lost (DALYs) worldwide (203). Pneumonia is one of the most 
common lower respiratory tract infections and is the eighth leading cause of 
death in the United States (23). Although first-line treatment for pneumonia is 
antibiotics, these tools are becoming increasingly dull against the defenses 
harbored by the causative microbes. Antibiotic resistance is responsible for 
nearly 20,000 deaths per year as well as an estimated $20 billion in excess 
healthcare costs (24). Furthermore, pharmaceutical development against these 
microbes has slowed to a trickle, with one new antibiotic approved in the last ten 
years. Our model of mTBI enhanced innate immunity may provide clues to 
augmenting the innate host response against invading pathogens. In addition, 
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antibiotic resistant organisms may be equally susceptible to host defenses as 
their antibiotic sensitive counterpart (45, 134). New approaches to combating 
these organisms will be required to overcome their increasing burden on 
healthcare.  
 
Pathophysiology 
Pneumonia is caused by invasion of microbes into the smallest air sacs, the 
alveoli. The release of pathogen-associated molecular patterns (PAMPs) or 
damage associated molecular patterns (DAMPs) into the tissue triggers signaling 
pathways to mount an immune response. Resident alveolar macrophages can 
sense or phagocytose microbes then produce pro-inflammatory mediators such 
as IL-1, IL-6 or TNF-α and chemotactic factors such as IL-8, CXC chemokines, 
and granulocyte-colony stimulating factor (G-CSF) (41, 136). Alveolar epithelial 
cells can also produce chemotactic factors, such as lungkine and CXCL5 (95). 
Host production of IL-8, leukotriene B4 (LTB4), and complement C5a combined 
with the bacterial formyl-met-leu-phe (fMLP) peptide are potent chemoattractant 
signals to recruit neutrophils to the site of infection. Neutrophils are 
polymorphonuclear cells (PMNs) that are the first responders of innate immunity 
to eliminate microbial invaders. These are responsible for early clearance of 
pneumonia. Microbes, cells, and vascular leak congest the airspaces, which in 
classical lobar pneumonia is seen as dense consolidation. After containing the 
infection, neutrophils undergo apoptosis which allows for macrophages to 
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phagocytose and clear them. Exposed phosphatidylserine on apoptotic 
neutrophils acts as a signal to macrophages to phagocytose them. This 
phagocytosis helps to resolve inflammation by inducing anti-inflammatory 
transforming growth factor-β1 (TGFβ1) production (93) which helps to return the 
tissue to a normal homeostasis.  
 
TBIs and Pneumonia 
The current clinical paradigm is that patients with TBI have an increased 
susceptibility to infections, with reports varying between 25 to as high as 50% 
developing an infection. A direct comparison between neurotrauma and non-
neurotrauma groups in a single-center study showed that neurotrauma patients 
have an increased risk of pneumonia (7). Pneumonia, especially ventilator-
associated, is one of the most common infections of TBI patients. Several 
retrospective analyses report that nearly 50% infections are from pneumonia (84, 
104, 219). Staphylococcus aureus (S. aureus), Pseudomonas aeruginosa (P. 
aeruginosa), Haemophilus influenza, Klebsiella pneumonia, and Acinetobacter 
species are reported as the most common microbial origins of infection (22, 59, 
104). A prospective study of closed head injury patients with mechanical 
ventilation (MV) showed that the etiology of early-onset (<4d) and late-onset 
(>4d) pneumonias were divided into gram-positive (ex. S. aureus) and gram-
negative bacteria, respectively (22). The combination of invasive medical 
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procedures, neurological deficits, and dysregulated neural input on the immune 
system contributes to increased risk of these patients of developing pneumonia. 
 
Clinical Risk Factors 
Patients suffering TBIs, especially those with low GCS scores, often 
present with clinical complications that predispose them to infections. Mechanical 
ventilation (MV) is a recognized risk factor for the development of pneumonia. A 
retrospective analysis of TBI patients requiring mechanical ventilation (MV) in the 
National Trauma Data Bank showed that each day of MV increased their risk by 
7% (89). TBI patients may present with respiratory dysfunction or develop 
neurogenic pulmonary edema (NPE), either of which may necessitate the 
initiation of MV. While the exact mechanism of NPE is unknown, early 
experiments showed that functional innervation of the lung is required (71). It is 
thought that a catecholamine surge after TBI causes generalized 
vasoconstriction that shifts fluid toward the pulmonary vasculature and this 
increase of hydrostatic pressure pushes fluid into the lung space. Another theory 
posits that the sympathetic storm directly damages the lung and/or induces 
cytokine signaling that increases the permeability of the pulmonary capillaries 
(18). Dysphagia and aspiration, especially prior to intubation, are also major risk 
factors for development of pneumonia in this group (14, 80, 207). One 
prospective study reported that aspiration prior to intubation increased the risk of 
pneumonia by 5.5-fold (14). Another study reported increased rates of 
  
12 
pneumonia in TBI patients with reduced functional oral intake scores, feeding 
tubes, or tracheostomies (80). Counterintuitively, a retrospective analysis of 
severe TBI patients showed that serum alcohol levels are positively correlated 
with increased survival (158). Serum ethanol levels are also associated with 
reduced rates of pneumonia in a linear trend of increasing blood alcohol content 
(75). Multiple factors are involved in TBI patients’ reported predisposition to 
developing pneumonia.  
 
 
Immunosuppression 
 Dysregulated neural signaling has been hypothesized to cause 
immunosuppression following TBI. As above, many hypotheses have been 
proposed, from heightened tonic vagal tone, sympathetic storms, HPA-axis 
activation, or a combination that ultimately results in depressed immune 
responses. In both clinical studies and experimental models of TBIs, subjects are 
found to have blunted responses to immune challenges. A prospective clinical 
study characterizing B-cell frequency and phenotype in TBI patients showed 
increased numbers of B-cells following injury, but decreased IL-10+ frequency 
and IL-10 secretion. However, the subset of TBI patients with a high proportion of 
IL-10+ B-cells developed pneumonia following admission with longer ICU duration 
and time on MV (30). In a prospective randomized pilot study, approximately 
65% of severe TBI patients had decreased absolute CD3+ and CD4+ 
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lymphocytes. Furthermore, patients who developed a respiratory infection within 
7 days of admission had a significantly lower number of CD4+ T-cells (132). 
 Experimental models of TBI support the paradigm that severe TBI can 
cause lung injury as rats developed pulmonary edema and protein leakage 
following TBI. These rats produced significantly less TNF-α in response to ex 
vivo stimulation of the whole blood. However, the severity of pneumonitis was not 
significantly different between sham injury and TBI rats (199). A mouse model 
showed a bimodal thymocyte loss, once within 3 days of injury and then again 
after 30 days, which coincided with depletion of splenic macrophages. In 
addition, blood monocyte counts were reduced within 24h through 30d following 
injury. TBI also polarized monocytes toward anti-inflammatory M2 phenotype. 
Importantly, at later time points, IL-12 and CCL5 expression were suppressed. 
Although no infectious challenge was presented to these mice, these alterations 
of peripheral immunity suggest immunosuppression following TBI (164). 
Interestingly, a study of severe TBI patients by Liao et al. showed elevated 
circulating PMN counts and pro-inflammatory cytokine expression. PMNs from 
TBI patients exhibited significantly increased expression of NADPH oxidase 
enzymes and ROS burst. Despite this increased oxidative burst, circulating 
neutrophils had decreased phagocytosis rates compared to trauma control.  
 
Neutrophil Recruitment 
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 Neutrophils are generated in the bone marrow and circulate through the 
blood until they are called upon to fight an infection. In the bone marrow, stromal 
cells express CXCL12 (SDF-1) that interacts with CXCR4 receptors on 
neutrophils to hold them in reserve (124). This CXCR4-CXCL12 disruption is 
required to release neutrophils from the marrow (56). Granulocyte-colony 
stimulating factor (G-CSF) is the major factor that regulates granulopoesis and 
neutrophil release from the bone marrow (181). G-CSF signaling decreases 
CXCL12 expression by stromal cells, leading to neutrophil mobilization (166). In 
severe, systemic infections, emergency granulopoesis takes place that rapidly 
expands the neutrophil reserves (127). Pathogen sensing by non-hematopoetic 
cells in tissues signal the production of G-CSF, GM-CSF, and IL-6 to vastly 
increase the number of neutrophils available to fight the infection. G-CSF 
signaling through the G-CSFR to janus kinases (JAK) leads to phosphorylation of 
signal transducer and activator of transcription 3 (pSTAT3). pSTAT3 stimulates 
CCAAT-enhancer-binding protein β (C/EBPβ), the main transcriptional regulator 
of emergency granulopoesis and increases Myc expression. Activation of 
C/EBPβ accelerates the cell cycle and proliferation of neutrophil progenitors 
(127). To exit, neutrophils transcellularly cross bone marrow sinusoidal 
endothelial cells and enter the vasculature (17).  
Neutrophils in the blood must be recruited to infectious foci. The primary 
neutrophil chemotactic factors LTB4, complement C5a, IL-8, and fMLP are 
produced during the course of infection. CXC chemokine (CXCL1, CXCL8 (IL-8) 
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and CXCL2/MIP-2) expression creates gradients for neutrophils to follow towards 
the source as they interact with their receptors, CXCR1 and CXCR2.  
Chemoattractant binding to receptors activate G protein-coupled receptors 
(GPCRs) that activate trimeric Gi proteins by dissociating Gαi and Gβγ signaling 
subunits. Downstream of Gβγ, phosphatidylinositol 3-kinases (PI3Ks) produce 
phosphatidylinositol 3,4,5-triphosphate (PI(3,4,5)P3), which accumulates at the 
edge of the neutrophil closest to the gradient. This PI(3,4,5)P3 accumulation 
causes DOCK2 to translocate and exchange GDP to GTP on Rac, which 
activates them. Rac transduces signals to the actin polymerization machinery to 
polarize and move the cell towards the source of the gradient. On the other side 
of the gradient, activation of G12 and G13 proteins initiate Rho-dependent signal 
transduction pathways to activate myosin II. Actin-myosin interaction on the 
backside of the neutrophil allows for contraction of the trailing edge to move the 
cell along, termed the “backness” pathway. The combination of both forward and 
“backness” pathways allows for chemotaxis down the gradient (200). 
To exit the vessels, PMNs undergo diapedesis, a multi-step process of 
extravasation and migration through the tissue. Neutrophils are slowed along the 
margins of the vessels by interactions of P-selectin glycoprotein ligand-1 (PSGL-
1) and P-selectin on endothelial cells. These interactions cause high-affinity 
integrins to be expressed on the cell surface that bind to ICAM or VCAM on 
endothelial cells to halt their movement. PMNs cross through the vessel through 
transendothelial cell migration (TEM), either by slipping between junctions of 
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adjoining endothelial cells (paracellular TEM) or through the cells themselves 
(transcellular TEM). TEM is assisted by platelet endothelial cell adhesion 
molecule-1(PECAM-1) protein interactions between cells. From here, neutrophils 
breach the basement membrane through either certain low density regions or 
through proteolytic cleavage (144). 
 
Neutrophil Killing 
First responders of innate immunity, neutrophils, have multiple ways to eliminate 
invading pathogens. Very early work showed phagocytosis with proteolytic 
degradation of microbes as killing mechanisms. Research has elucidated the 
specifics of multiple intracellular killing mechanisms. However, even recently, 
new neutrophil weapons, such as extracellular mechanisms are being described 
that show the diversity of neutrophils’ armament against microbes. 
 
Phagocytosis 
Neutrophils use phagocytosis as a major mechanism for the clearance of 
pathogens by engulfing them for subsequent killing. Phagocytosis can be 
mediated by PAMP-pattern recognition receptor (PRR) interactions, FcγR binding 
of IgG opsonized microbes, or complement receptor mediated killing. FcγR 
binding clusters multiple receptors to place their cytosolic domains containing 
immunoreceptor tyrosine-based activation motif (ITAM) regions close together. 
Src family kinases phosphorylate both available tyrosine sites. ITAMs are then 
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bound by phosphorylated spleen tyrosine kinase (Syk) that recruits signaling and 
adaptor proteins to recruit further signaling that induces changes in the 
membrane and mobilizes actin machinery that allows the cell to envelop its target 
(61, 114). Complement mediated phagocytosis occurs through activation of the 
integrins by complement ligands, such as iC3b. Integrin-complement binding 
causes signaling through RhoA. RhoA activates Rho kinase to phosphorylate 
myosin II and causes mDia1 recruitment to the phagocytic cup to activate two 
pathways of actin polymerization machinery to engulf the target (61). Microbes 
taken up by neutrophils are contained within phagosomal vacuoles (phagosome). 
These phagosomes are initially immature and only become microbicidal following 
phagosomal maturation, which involves phagosomal fusion with neutrophil 
granules and formation of the NADPH oxidase complex.  
 
Granules 
Neutrophils contain granules, collections of microbicidal proteins within their 
cytoplasm. Primary granules contain myeloperoxidase (MPO), lysozyme, serine 
proteases, and defensins. Neutrophil proteases (neutrophil elastase and 
cathepsin G) from the primary granules are a major source of microbicidal activity 
(156). Secondary (or specific) granules are smaller and characteristically contain 
lactoferrin, transcobalamin, and lipocalin. Tertiary granules are known as 
gelatinase granules because they contain metalloproteases. Secretory vesicles 
containing plasma proteins and receptors are considered the last type of granule 
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(165). Granules can fuse with the plasma membrane to extrude contents into the 
extracellular space or fuse with phagosomes containing microbes, which is called 
phagosomal maturation. Granules are mobilized in reverse order to facilitate the 
steps of neutrophil killing.  Early work by Lew et al. showed that each of these 
granules have a different cytosolic calcium threshold proportional to their 
sequential activation (117). Secretory granules are easiest to mobilize and head 
to the membrane to expose the internalized receptors for chemotaxis, 
phagocytosis, or diapedesis. Gelatinase granules are next to be secreted as they 
contain the metalloproteases that cleave a path for the homing neutrophil. 
Secondary granules can fuse with the plasma membrane to release their 
proteins. Primary granules are trafficked to the maturing phagosome to kill the 
engulfed microbes (76).  
 
Reactive Oxygen Species (ROS) 
The NADPH oxidase system of neutrophils governs the production of ROS in 
neutrophils by inserting into the membrane of the phagocytic vacuole. Patients 
with defects of genes required for this system (CYBB, CYBA, NCF1, NCF2) 
suffer from chronic granulomatous disease, characterized by recurrent bacterial 
infections. The core of NADPH oxidase system is flavocytochrome b558 
composed of one p22phox and one gp91phox subunit. The gp91phox(encoded by 
CYBB gene) consists of two domains responsible for the transportation of 
electrons across the membrane. p22phox (encoded by CYBA gene) contains a 
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membrane spanning N-terminus for binding to cytosolic components of the 
NADPH oxidase system. In the cytosol, p67phox (NCF2) is shuttled by p40phox to 
the phagocytic membrane where it binds to the flavocytochrome to induce 
electron transport. p47phox (NCF1) bridges interactions between p22phox and 
p67phox. p47phox can also bind to gp91phox to stabilize p67phox-flavocytochrome b558 
interactions. p21rac is a guanosine 5’-triphosphatase (GTP)-dependent protein 
necessary for activation of the NADPH oxidase complex (165).The completed 
NADPH oxidase system pumps in superoxide (O2
-) where it can react with MPO 
to produce hypochlorous acid (HOCl) to kill microbes contained within the 
phagocytic vacuole.  
 
Phagosomal Maturation 
Neutrophil microbicidal activity is thought to be mediated by ROS generation and 
the activity of neutrophil proteases. NADPH complex formation supplies O2
- to 
MPO for HOCl production. The initial consumption of H+ ions transiently elevates 
the pH of the phagosome and causes K+ to flux in through a calcium sensitive 
BKCa channel to compensate for the loss in charge. Granule fusion brings in 
cationic neutral proteases bound to an anionic proteoglycan matrix. The 
hypertonic influx of K+ disrupts these charge interactions and frees the proteases 
while the consumption of H+ causes the pH to be at the optimal neutral level for 
microbial killing, despite the entry of acidic granule contents. Cytoskeletal 
components surrounding the vacuole prevent loss of hypertonicity to aid killing, 
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as some azurophilic granule proteins are inactivated at physiologic 
concentrations of salts. Alteration of the vacuolar environment during 
phagosomal maturation is thought to be a mechanism designed to limit collateral 
damage (165).  
 
Antimicrobial Proteins 
Neutrophils also produce antimicrobial proteins to assist with microbicide acting 
through various mechanisms. Cationic peptides like α-defensins or cathelicidins 
can induce pores in bacterial cell walls and their positive charge helps them to 
interact with bacterial peptides. Defensins were shown to be bactericidal towards 
both gram positive and negative bacteria, as well as fungicidal. These actions 
were due to binding of defensins to the bacterial membrane that results in 
permeabilization (163). The human cathelicidin LL-37 was shown to kill 
pathogens, such as Pseudomonas aeruginosa, E. coli, and Candida albicans. 
Using an E.coli expressing β-galactosidase without its transporter and 
periplasmic β-lactamase, experiments showed that both inner and outer bacterial 
membranes were permeabilized by cathelicidin (191). In addition, LL-37 changes 
confirmation to bind to LPS. Proteolytic enzymes, most notably lysozyme and 
neutrophil elastase, cleave apart bacterial membranes. Other proteins, such as 
lactoferrin can chelate metals necessary for bacterial growth (128).  
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Neutrophil Extracellular Traps (NETs) 
Neutrophils can release NETs in response to infections to limit the spread of 
microbes and eliminate them. In “NETosis”, neutrophils decondense their 
chromatin, disintegrate their granules, and extrude cellular contents into their 
surroundings. Initiation of this process requires ROS activity generated by intact 
NADPH and MPO systems (63, 135). NETs are ~17nm filaments studded with 
granular proteins that encompass an area approximately 10-15 times the size of 
the cells. Microbes can be trapped through charge interactions with the NETs. 
Microbicidal peptides, enzymes, histones, and DNA itself have all been shown to 
participate in NET-induced pathogen killing. (12, 78, 168). NETs have been 
shown to have trapping, if not direct killing, activity in a wide variety of pathogens 
from bacteria, to fungi, to viruses (212). Formation of NETs intravascularly was 
shown to limit dissemination of bacteria that requires platelet-neutrophil 
interaction. Using fluorescently labeled E.coli injected intraperitoneally, McDonald 
et al. demonstrated that NETs trap bacteria and disruption of the platelet-
neutrophil interaction or digestion of NETs by DNAse allowed significant 
dissemination to the blood and lungs. By trapping pathogens in close proximity to 
high concentrations of microbicidal components, NETs are another tool in the 
neutrophils’ arsenal.  
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Trauma and Innate Immunity 
Vagus/inflammatory reflex signaling background 
The inflammatory reflex is a neural circuit that dampens pro-inflammatory 
responses via the vagus nerve. Peripheral noxious signals, such as PAMPs or 
DAMPs, trigger the production of IL-1 and pro-inflammatory cytokines in the 
periphery to alert the CNS through the afferent arc of the vagus. Nociceptive pain 
signals are also transmitted by release of substance P from afferent fibers. 
Afferent signals are relayed to the nucleus tractus solitarius in the brainstem. 
Synaptic relays connect these to the nucleus ambiguus and the dorsal vagal 
motor nucleus, which are the outflow pathways of the vagus. Efferent fibers of 
this circuit travel from the brain to the celiac ganglion. Fibers from the celiac 
ganglion comprise the splenic nerve (189). However, the splenic nerve only 
releases catecholamines in response to stimulation and it has been shown that 
norepinephrine signals to lymphocytes to release acetylcholine (ACh), which is 
neurotransmitter responsible for the anti-inflammatory actions (161). Thus, the 
vagus nerve controls immune responses through afferent and efferent nerves 
forming a reflex arc.  
 
Afferent Arc - Substance P and Innate Immunity 
Substance P (SP) is an 11-amino acid peptide known as a nociceptive, pain-
sensing molecule. Afferent vagal sensory neurons release SP in response to 
stress or stimulation (97, 126). TBIs induce release of SP following injury that is 
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proportionally related to the severity of injury (122, 216) and is thought to drive 
neurogenic inflammation resulting in further organ damage. Rat models show 
that SP release drives brain edema and functional deficits. In these models, 
treatment with SP antagonists show decreased neurologic deficits reflected by 
diminished axonal injury (49, 50) and these results propose NK1R antagonism as 
a target for therapeutic neurologic interventions in patients. 
The primary receptor, neurokinin-1 (NK1R), exists in two different 
isoforms: a full length and a truncated form lacking the C-terminus. Ligand 
binding to full length NK1R couples with Gq/11 proteins to lead to activation of 
phospholipase C-β (PLC β) to induce increases in inositol 1,4,5 triphosphate 
(IP3) and diacyl-glycerol (DAG) second messengers. Truncated NK1R activate a 
different G protein pathway separate from the Gq/11 interactions with the full 
receptor (190). These signals induce intracellular calcium release to induce 
various effects based on the cell expressing NK1R. SP activation of NK1R 
induces various effects on tissues, such as vasodilation, leukocyte adhesion to 
endothelial cells, itching, bronchoconstriction, and altered gut motility (81). NK1R 
binding can also activate adenylyl cyclase to produce cAMP that leads to 
separate signal transduction pathways. Full length NK1Rs mobilize Ca2+, quickly 
activate NF-κB and extracellular-signal-regulated kinase (ERK) pathways, and 
cause production of IL-8. Truncated receptors do not mobilize Ca2+ or produce 
IL-8, and only slowly activate ERK signaling (52).  
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 NK1R activation can enhance multiple facets of immune function. SP 
signaling has previously been shown to enhance neutrophil chemotaxis and 
production of chemotactic factors (182). Neutrophils are also primed by SP to 
produce more ROS, exocytosis of granules, and mobilization of Ca2+ (16, 167). 
Interestingly, SP-evoked Ca2+ changes only happen in the presence of a 
secondary stimulus, such as IL-8 (47). This suggests that SP primes but does not 
indiscriminately activate neutrophils. Macrophages also have increased 
phagocytosis in response to SP treatment (69) and increased cytokine 
production (62). These examples show how SP signaling can have diverse 
augmenting effects on immune function in the clearance of microbes.  
 
Efferent Arc – Acetylcholine and the Inflammatory Reflex 
The efferent arc of the inflammatory reflex is mediated by the actions of the α7 
nAChR (encoded by the Chrna7 gene) and is known as the cholinergic anti-
inflammatory pathway. Activation of this pathway is critical to the downregulation 
of pro-inflammatory cytokine production. α7nAChR knockout (KO) and 
vagotomized mice have uncontrolled inflammation when challenged by endotoxin 
(10, 202). Acetylcholine binding to the α7 receptor can inhibit phosphorylation of 
the inhibitor of NF-κB (IκB), transiently release intracellular Ca2+ that decreases 
MAPK phosphorylation, or form a heterodimer with JAK2 to activate STAT3 and 
SOCS3. Although this has been termed an anti-inflammatory pathway, it does 
not increase the production of anti-inflammatory cytokines, such as IL-10 (10). 
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Studies of α7 nAChR signaling in innate immunity show that agonist stimulation 
of the pathway blocked TNFα activation of endothelial cells, reduced adhesion 
molecule expression, and leukocyte recruitment (162). Other work showed that 
α7 agonist treatment could inhibit neutrophil recruitment in a TNFα independent 
manner (68).  
 Hyperactivity of the vagus nerve through this pathway has been proposed 
to generate an immunosuppressive state (77, 106) in TBI patients. Increased 
vagal tone in the absence of an inflammatory stimulus shifts the balance towards 
a tonic anti-inflammatory state, which results in a predisposition to infections. 
However, recent evidence in experimental models of TBI suggests that α7 
nAChR activation reduces BBB permeability and inflammation that causes 
secondary injury (43). Exploitation of this pathway has proven beneficial in 
various inflammatory and infectious disorders (105, 116, 148). Further research 
is required to elucidate the true role of this pathway.  
 
Severe traumatic brain injury has been classically associated with an 
immunosuppressed state and a predisposition to infections. However, analysis of 
the National Trauma Data Bank using propensity score matching of blunt, non-
head or chest trauma versus head-trauma patients showed that TBI patients had 
reduced rates of pneumonia, as well as reduced length of ICU and/or hospital 
stay. Our lab developed a murine model of mild TBI (mTBI) that recapitulates the 
clinical scenario. mTBI mice challenged with bacterial pneumonia have reduced 
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mortality that is characterized by increased cell recruitment and bacterial 
clearance in the airspaces (209). This mTBI model allows us to study potential 
mechanisms of enhanced innate immunity that may be translated to human use.  
 
To test whether any trauma can prime the organism for a second challenge, we 
characterize and compare a mild tail trauma model against our mTBI model. 
Neural input on immunity, especially through the vagus nerve, was of particular 
interest. These studies focus on the mechanism of SP in mTBI improved survival, 
specifically neutrophil functions, such as chemotaxis and microbial killing. In 
addition, we investigate the contribution of inflammatory reflex signaling on 
dampening the production of pro-inflammatory mediators to improve survival 
following mTBI.  
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Chapter 2: Mild Traumatic Brain Injury But Not Tail Trauma Augments 
Pulmonary Clearance of Bacteria Via Release of Substance P 
 
Introduction 
Neural input exerts significant control on the ability of the immune system 
to effectively clear pathogens. Early studies demonstrated that stress has a 
profound detrimental effect on the immune response (177). Psychologic or 
physiologic stress can result in dysregulation of these pathways, such as chronic 
activation that ultimately leads to immunosuppression (146). Activation of the 
vagus nerve has also been shown to exhibit powerful anti-inflammatory effects 
through the α7 nicotinic acetylcholine receptor (α7 nAChR). In severe TBI 
patients, it has been proposed that hyperactivity of the vagus depresses immune 
responses through strong dampening of pro-inflammatory mediator production 
(82). In contrast to these studies showing that the neuro-immune axis decreases 
immune responses, our previous work documented that head trauma patients 
exhibited significantly reduced rates of pneumonia compared to blunt trauma 
patients (209). A murine model of mild traumatic brain injury (mTBI) was able to 
reproduce these findings with enhanced resistance to bacterial pneumonia 
compared to sham injury mice (209). mTBI mice exhibited improved survival, 
augmented pulmonary neutrophil recruitment, and reduced bacterial burdens. 
These findings show that neuroimmune modulation can exhibit beneficial effects 
by improving immune function. Further investigation into the mechanisms by 
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which this model augments the innate immune response could offer valuable 
insight into fighting infections in today’s increasingly antibiotic resistant world 
(24).  
An important question raised by the previous study was whether any mild 
trauma would augment host resistance to bacterial pathogens. To address this 
issue, a model of peripheral injury was needed for comparison. In our previous 
clinical study, the blunt non-head trauma patients were used as controls, but our 
murine studies used sham injured mice. Traumatic injury models have been 
shown to have drastic effects on immunity. For example, a pulmonary contusion 
model displays enhanced neutrophil recruitment and expression of inflammatory 
mediators to an intratracheal LPS challenge (87). However, unlike our mTBI 
model, these neutrophils were ultimately deleterious and caused lung injury. 
Fracture and pseudofracture models replicate a common clinical injury and can 
have powerful immunosuppressive effects (118, 141). These disparate effects 
demonstrate the wide spectrum of immune alterations and the necessity for 
proper controls in studying traumatic sequelae. These prior publications raise the 
concern that any mild trauma could alter the host immune response and that the 
protective effects seen in our mTBI model are not specific to head trauma. Thus, 
we sought to develop an injury model that induces similar hematologic, 
physiologic and inflammatory changes without compromising the lung, our 
primary organ of interest. A model of blunt tail trauma was studied to test the 
hypothesis that only traumatic brain injury will augment pulmonary anti-bacterial 
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defenses. The current study also demonstrated that specific blockade of 
substance P signaling decreased survival to a pulmonary pathogen only in mTBI 
mice, confirming the mechanism of the improved survival (209). The significance 
of this work is further highlighted by a 2015 paper showing that TBI patients had 
increased levels of substance P (122). 
 
Materials and Methods 
Animals 
Female ICR mice (Harlan Sprague Dawley, Indianapolis, IN) were used for all 
experiments. All mice were 8-10 weeks old, weighed between 24-30g, and were 
acclimated for at least 3 days prior to experiments. Animals were housed in a 
temperature and humidity controlled facility with a 12-hour light/dark cycle. Food 
and water were provided ad libitum. The Institutional Animal Care and Use 
Committees at Boston University approved all experiments. The neurokinin-1 
receptor (NK1R) is the preferred receptor for substance P (52). The NK1R 
antagonist, aprepitant (50mg/kg, Merck, 2% carboxymethylcellulose (CMC, 
Sigma) was given 2h prior to trauma and afterwards at 12h intervals by oral 
gavage (p.o.) until pneumonia instillation. Vehicle mice were administered 2% 
CMC p.o. 
 
Trauma and Pneumonia models 
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Mild traumatic brain injury was performed as previously described (209). Mice 
were evaluated 2h post-injury using our modified mouse coma scale (MMCS) 
(Table 1) by two blinded evaluators and only mice meeting the criteria for mild 
TBI (MMCS > 13) were included. >95% of mice hit had a MMCS >13, mice with a 
MMCS < 13 at 2h were excluded. To induce mild tail trauma (TT), mice were 
anesthetized using isoflurane and placed in a prone position on the surface of the 
mTBI apparatus. The 170g steel rod was released from a height of 8.5cm onto a 
spot 2.0cm from the base of the tail. This height was chosen based on pilot 
studies where it induced neutrophilia at 4h similar to the mTBI mice. Immediately 
following impact the mouse was removed and given a subcutaneous injection of 
0.05mg/kg buprenorphine in 1mL of normal saline. Mice are placed on a warming 
pad until they are able to right themselves. Mice were randomly selected to 
undergo TBI, tail, or sham injury. Sham injury mice were chosen at random to 
undergo either a mock mTBI or tail trauma without injury. Pneumonia was 
induced 48 hours post-trauma by administration of 0.5-1x108 CFU of 
Pseudomonas aeruginosa (ATCC strain Boston 41501) in 50uL of Hank’s 
balanced salt solution (HBSS) by intratracheal instillation as previously described 
(209). 
 
Hematological Analysis: 
20uL of blood was collected from the facial vein at serial time points into 180uL of 
PBS-EDTA (50:1) and centrifuged for 5 minutes at 1000g (40). Plasma was 
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removed for later analysis while the pellets were resuspended in Hemavet diluent 
and used to obtain a complete blood count with differential using a Hemavet 950 
instrument (Drew Scientific, Miami Lakes, FL). 
 
Physiologic and Respiratory Parameters 
Physiologic measurements (heart rate, O2 saturation, and pulse distension) were 
obtained by cervical collar telemetry (MouseOx, Starr Lifesciences, Oakmont, 
PA). Respiratory measurements (respiratory rate, time of inspiration/expiration, 
and tidal volume) were also measured using unrestrained whole body 
plethysmography (Buxco Research Systems, Wilmington, NC). Initial readings 
were taken on the day prior to trauma and then at 4h, 24h, and 48h following 
injury.  
 
Tissue Samples 
Mice were sacrificed under ketamine/xylazine anesthesia. Bronchoalveolar 
lavage (BAL) was performed 4h after instillation of Pseudomonas with 5mL of 
warm HBSS-EDTA (50:1) in 500uL aliquots. Of the first 1mL, 100uL was taken to 
determine bacterial burden by serial dilutions on 5% sheep’s blood agar plates. 
Cell pellets were combined and counted using a Beckman-Coulter particle 
counter (Coulter Electronics, Danvers, MA). A cell differential was performed by 
counting 300 cells spun using a Cytospin (Shandon) and slides stained with Diff-
Quick. Mice were sacrificed at 30 min or 120 min after mTBI to collect blood and 
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BAL fluid. Substance P concentrations in samples were measured by ELISA 
using a commercial kit (Substance P ELISA Kit, Cayman Chemical Co, Ann 
Arbor, MI). 
 
Injury Quantification 
To quantify the extent of plasma leakage from the vasculature, 1% bodyweight of 
a 1% Evans blue solution was injected intraperitoneally (i.p.) 1h prior to trauma. 
Mice were sacrificed 48h post-trauma using ketamine/xylazine anesthesia, then 
perfused with PBS-Heparin (10U/mL) followed by 10% formalin. Whole brain and 
a 1.5cm long section of the tail encompassing the injury site were collected. 
Tissues were stored in 10% formalin. 2mm (brain) or 3mm (tail) slices were 
imaged using an Odyssey near-infrared scanner (Li-Cor, Lincoln, NE) to measure 
Evans’ blue extravasation from the vasculature and tissue penetration. Tissue 
slices were then embedded in paraffin blocks for sectioning, hematoxylin/eosin 
staining, and histological analysis. Glass slides were scanned on iScanCoreo 
(Ventana, Tuscon, AZ). 
 
Measurement of Coagulation Parameters 
Samples were analyzed by Evan Catudal of the Kurosawa laboratory.  
Fibrinogen  
Plasma fibrinogen concentrations were determined using a Thrombin Clotting 
Time (TCT) assay performed on a Sigma Amelung KC4 Delta™ coagulation 
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analyzer (Trinity Biotech, Wicklow, Ireland). The TCT assay measures the time it 
takes for a clot to form in plasma containing an anticoagulant (3.8% sodium 
citrate) following incubation at 37° C and addition of excess thrombin).  
 A fibrinogen standard curve was prepared using pooled plasma standard 
with a known concentration of 130 mg/dL diluted 1:5, 1:10, and 1:20 in imidazole 
buffer. Unknown mouse plasma samples were diluted 1:10 in imidazole buffer. 
100uL of diluted mouse plasma was added to individual KC4 Delta™ Tetravette 
wells in duplicate and incubated at 37° C for 60 seconds. 50uL of dilute thrombin 
was then added to each sample well and the time it took for a clot to form was 
recorded by the electronic timer on the coagulation analyzer. Replicate results 
with greater than 10% difference were rejected and rerun. The TCTs from the 
unknown samples were compared to the standard curve in order to determine 
their fibrinogen concentrations 
D-dimer 
D-dimer levels were measured using an Asserachrom D-Di (Diagnostica Stago, 
S.A.S., Asnières sur Seine, France) ELISA Kit and unknown D-dimer values 
were calculated from the standard curve using the manufacturer-provided human 
D-dimer standards. All unknown samples were diluted 1:21. The ELISA plate was 
read using a VersaMax Microplate Reader (Molecular Devices, Sunnyvale, CA) 
and the results were analyzed using SoftMax Pro 5.4 data analysis and 
acquisition software (Molecular Devices, Sunnyvale, CA). 
PAI-1 
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PAI-1 levels were measured using an Abcam PAI-1 Total Mouse ELISA kit 
(Abcam plc, Cambridge, United Kingdom). The ELISA plate was read using a 
VersaMax Microplate Reader (Molecular Devices, Sunnyvale, CA) and the 
results were analyzed using SoftMax Pro 5.4 data analysis and acquisition 
software (Molecular Devices, Sunnyvale, CA). 
 
Cytokine measurements 
Cytokines were measured by sandwich ELISA using matched antibody pairs and 
standards purchased from R&D systems (Minneapolis, MN). The ELISA plate 
was read on a Tecan SpectraFluor Plus (Switzerland) and analyzed using Tecan 
Magellan software. 
 
Substance P 
Mice were sacrificed at 30 min or 120 min after mTBI to collect blood and BAL. 
Supernatants were collected as previous described. Substance P concentrations 
in samples were measured by competitive binding ELISA using a commercial kit 
(Substance P ELISA Kit, Cayman Chemical Co, Ann Arbor, MI). 
 
Statistical Analysis 
Statistical analyses were performed using Prism 6.0 Software (GraphPad, La 
Jolla, CA). Hematological, physiological, and pulmonary data were analyzed by 
two-way ANOVA, with Bonferroni post-tests where appropriate. Survival data 
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was analyzed by log-rank tests. Comparisons between mTBI and TT after 
pneumonia challenge were made using a two-tailed Student’s t-test. Analysis 
between three or more groups was performed by one-way ANOVA with Tukey’s 
post-test.  
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Results 
Tail and Head Trauma induce similar inflammatory hematological changes 
In order to test the hypothesis that only head trauma primes the immune 
system, we developed a model of peripheral injury with a similar level of injury as 
our mTBI. Tail trauma (TT) by weight drop was chosen as it avoids several 
potential confounders. First, our studies focus on the immune response to 
pneumonia and tail trauma would not compromise pulmonary or diaphragmatic 
function (87, 142). Second, this model closely mimics our closed-head mTBI 
model that avoids skin manipulations and potential damage to organs implicated 
in mounting immune responses (209). Third, as in our mTBI model, we avoid 
bone fractures that are known to be immunosuppressive (118, 141). Since 
virtually any trauma induces an inflammatory response, including neutrophilia 
related to the severity of the injury, we first analyzed hematological changes. 
Both mTBI and TT groups exhibit similar early neutrophilia 4h after injury (Fig 
1A), indicating that both models induce a detectable level of trauma. 
Concomitantly, the lymphocyte concentration in both groups decreased in an 
expected fashion (Fig 1B). Total WBC count did not significantly differ (Fig 1C). 
There were no significant differences between trauma groups at the time points 
analyzed by two-way ANOVA. Comparable elevations in neutrophils suggest that 
neither method induces a higher level of trauma. The normalization of 
hematological alterations by 24h suggests that differences in circulating immune 
cell numbers do not contribute to enhanced immune responses. 
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TT and mTBI induce physiologic responses that normalize within 48 hours 
Additional experiments sought to characterize changes following injury to 
determine whether physiologic differences were induced by the trauma and if 
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Figure 2-1.Hematologic changes following brain or tail trauma. 
Both groups exhibit similar hematological changes following trauma. (A) Trauma 
induces neutrophilia in both groups that resolves by 24h. (B) Lymphocytes 
decreased at the 4 hour time point in both groups. (C) The total white blood count 
(WBC) was unchanged. Data shown as mean±SEM. No significant differences 
were found by two-way ANOVA.  (n = 8 for mTBI, n = 12 for Tail) 
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they persisted up to the time of the pneumonia challenge. Physiological 
measurements of heart rate, pulse distension (a measure of local arterial blood 
flow proportional to cardiac output), and O2 saturation were measured using 
cervical collar telemetry. The telemetry data allowed repeated measurements on 
the same experimental subject to see the onset and resolution over the 48 hours 
post injury. There were no significant differences between TT and mTBI mice in 
heart rate during the 48h following injury, (Fig 2A). While pulse distension (Fig 
2B) was significantly higher in TT mice, and O2 saturation (Fig 2C) lower at 4h 
following trauma, these normalized by 24h. 
 
Since we would be inducing a pulmonary pathogen additional pulmonary studies 
were performed with an alternative technology. Respiratory parameters were 
measured by unrestrained whole body plethysmography (WBP) (194). Tidal 
volume remained essentially unchanged in both trauma models (Fig 3A). Both 
trauma models had a significant decrease in respiratory rate (Figure 3B) due to 
increased time of inspiration (Figure 3C) and expiration (Figure 3D) with greater 
changes in the mTBI group. All three of these differences were normalized by 
24h. These results show that the relatively minor, early physiologic and 
respiratory differences between models at 4h resolved by 24h. The systemic 
measurements support that both models exhibit similar responses through the 
first 48h following trauma.  
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Figure 2-2. Early hemodynamic changes after trauma. 
 Differences between mTBI and tail trauma mice return to baseline at 24h. 
(A) There was no significant difference in the heart rate at any time point. 
(B) Pulse distension was higher in TT mice at 4 hours and (C) O2 saturation 
lower, but both returned to normal within 24 hours. Hemodynamic data 
collected from cervical collar telemetry (MouseOx). Data shown as 
mean±SEM (n = 5 for mTBI, n = 8 for Tail) 
 
  
40 
  
R e s p ira to ry  R a te
0
2 0 0
4 0 0
6 0 0
0 4
2
4
4
8
**
T im e  p o s t- in ju ry  (h )
B
r
e
a
t
h
s
 p
e
r
 M
in
u
t
e
T im e  -  In s p ir a t io n
0 .0 0
0 .0 5
0 .1 0
0 .1 5
0 .2 0
0 4
2
4
4
8
***
T im e  p o s t- in ju ry  (h )
T
im
e
 (
s
)
T id a l V o lu m e
0 .0
0 .1
0 .2
0 .3
0 .4
m T B I
T a il
0 4
2
4
4
8
***
T im e  p o s t- in ju ry  (h )
V
o
lu
m
e
 (
m
L
)
T im e  -  E x p ira t io n
0 .0 0
0 .0 5
0 .1 0
0 .1 5
0 .2 0
0 .2 5
0 4
2
4
4
8
***
T im e  p o s t- in ju ry  (h )
T
im
e
 (
s
)
A B
C D
 
Figure 2-3. Pulmonary physiology measured by whole body plethysmography.  
Both groups of trauma exhibit similar respiratory parameters by 24h after 
trauma. (A) mTBI mice had lower tidal volumes overall but exhibit the same 
trend as tail trauma while returning to their baseline level by 48h. (B) 
Respiratory rate, (C) time of inspiration (Ti), and (D) time of expiration (Te), 
were significantly different between groups only at the 4h time point, but 
normalized by 48h. Data obtained by unrestrained whole body 
plethysmography at the time points indicated. Data shown as mean±SEM. (n 
= 5 for mTBI, n = 8 for Tail). **=p<0.01, *** = p<.001 TT compared to mTBI. 
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TT and mTBI mice display divergent acute phase responses to trauma 
 As physiologic parameters were similar between the TT and mTBI mice, 
we sought to investigate other signs of priming. The acute phase response is 
induced by trauma or infection and increases plasma concentration of various 
proteins. We measured acute phase proteins in the 48h after trauma to examine 
whether mTBI and TT mice exhibited similar responses. Measures of 
coagulation, fibrinogen, plasminogen activator inhibitor-1, and d-dimer were 
measured (Fig 4. A). mTBI showed elevated fibrinogen production 24h following 
injury that was sustained until 48h (Fig 4. A). Both trauma models increased PAI-
1 at 24, however at 48h, the responses diverged and mTBI PAI-1 continued to 
elevate (Fig 4. B). No significant differences between D-dimer were found (Fig 4. 
C). IL-6 is an important protein in driving the acute phase response, and is known 
to drive serum amyloid A (SAA) production. IL-6 was undetectable in TT mice 4h 
following injury, but significantly elevated in mTBI mice (Fig 4. D). Plasma SAA 
concentrations at 24h reflected IL-6 production, with mTBI mice having 
significantly higher levels than TT mice (Fig. 4 E). These data show that the 
acute phase response is different between the trauma models. We hypothesize 
that these changes may be evidence that only mTBI primes the host for a second 
insult.  
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Figure 2-4. Measurement of the acute phase response.  
mTBI mice exhibit an increased acute phase response. Fibrinogen was 
measured by thrombin clotting time. All other measures were measured by 
sandwich ELISAs. (A) Fibrinogen was significantly increased in mTBI mice at 
24 and 48h after trauma. (B) At 48h, mTBI had increased PAI-1 compared to 
TT. (C) D-dimer showed no differences. (D) mTBI mice showed increased IL-6 
levels 4h post-trauma. (E) mTBI mice showed significantly increased levels of 
SAA. Data shown as mean±SEM. (A-C) analyzed by two-way ANOVA with 
Bonferroni post-test. (D-E) analyzed by student’s t-test. *p<0.05, **p<0.01, 
***p<0.001 compared to TT. Data for (A-C) collected by Evan Catudal of the 
Kurosawa Lab. 
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Assessing Neurological Injury: Modified Mouse Coma Scale 
Our data indicate similar systemic responses to trauma but additional 
experiments were performed to quantify the severity of neurological injury in our 
mice. The Glasgow Coma Scale (GCS) is the most commonly used neurologic 
injury scale for adults for traumatic head injuries (187). We adapted the GCS 
criteria to mice (Modified Mouse Coma Scale, MMCS) by observing their 
spontaneous behavior, response to auditory stimuli, and motor reflex responses 
similar to a clinical evaluation. This MMCS allows us to quickly and accurately 
assess the severity of neurological deficits (Table 1) as well as limit inter-
observer variability. To mimic the clinical scenario of a patient presenting to the 
emergency department for evaluation after head injury, two blinded investigators 
scored the mice 2h following trauma. This time point was chosen to recapitulate 
the common delay between injury and clinical evaluation as well as the superior 
performance of the two hour evaluation as a predictor of outcome (115). These 
same mice were also evaluated at 24 and 48h after trauma to longitudinally track 
any deficits in neurological function. The same GCS score for TBI severity was 
used in our MMCS where mild = 13-15, moderate = 9-13, and severe = <8. Our 
head trauma model reproducibly generated scores in the mild range and tail 
trauma mice exhibited no deficits at all (Fig 5). Less than 5% of mice had MMCS 
scores <13 and were excluded from the study. The results show that our TBI 
model consistently falls under the mild category and the MMCS can be used as a 
robust tool for assessing head trauma severity in mice. 
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Human Glasgow Coma Scale Mouse Coma Scale 
Eye 
Opening 
Spontaneous 4 
Posture 
Moving about cage 4 
To command 3 Hunched 3 
To pain 2 Dazed sternal recumbence 2 
None 1 Prone 1 
Verbal 
Response 
Oriented 5 
Response 
to Sound 
Turns to investigate 5 
Confused, 
disoriented 
4 
Moves away 
4 
Inappropriate 
words 
3 
Startle 
3 
Incomprehensible 
sounds 
2 
Wincing (no body movement) 
2 
None 1 No response 1 
Motor 
Response 
Obeys 
commands 
6 
Tail Lift 
Response 
Extension and reaching 
6 
Localizes pain 5 Extension without reaching 5 
Withdraws 4 Lifts head flexion 4 
Abnormal flexion 
to pain 
3 
Flexion no head lift 
3 
Abnormal 
extension to pain 
2 
Deviates to one side 
2 
None 1 No response 1 
Best total score 15     15 
Table 2-1. Modified Mouse Coma Scale 
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Characterization of injury sites 
To characterize the location of injury following trauma, we performed 
detailed analyses of tail and brain tissue from both groups at 48h following injury, 
i.e. at the time immediately prior to pulmonary pathogen challenge. Evans’ blue 
dye was injected intraperitoneally prior to the trauma to allow us to visualize and 
quantify the injury. Evans’ blue is a fluorescent dye that binds to serum albumin 
with high affinity and is unable to cross the intact blood brain barrier (BBB). 
These properties allow us to identify the area of injury, notably extravasation from 
the vasculature into tissue spaces, by its blue coloration as well as quantify the 
signal intensity using the LiCor Odyssey near-infrared scanner.  
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Figure 2-5. Modified Mouse Coma Scale (MMCS) scores.  
The MMCS showed no significant neurologic impairment in the mTBI model. 
Animals were evaluated by two blinded investigators at each time point 
using our MMCS (Table 1). Tail trauma mice had no deficits in scoring at 
any time points. No significant differences were found between groups at all 
time points. Data shown as mean±SEM (n=6 per group). 
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Near-infrared Quantification 
Evans’ blue fluorescence can be detected at 700nm using the Odyssey 
near-infrared scanner. mTBI mice showed an intense signal in the area of injury 
that reflects the histology damage described below (Fig 6A, right). TT brains 
have a slight signal due to the blood vessels in the brain (Fig 6A, left). 
Accordingly, TT tails reflect intense signal throughout the sections while mTBI tail 
signal is limited to the vasculature (Figure 6D left/right, respectively).  
H&E Sections 
Brains of mTBI mice show focal lesions with acute necrosis and 
hemorrhage generally involving the anterior and ventral portion of the brain. The 
ventral pallidum and anterior commissure were the most common structures 
damaged in the brains. No lesions were identified in any of the brains of tail 
trauma mice (Fig 6B). Tails of TT mice reflect the damage seen grossly with 
areas of extravasated RBCs in the tissue space, and infiltration of neutrophils 
(Fig 6E). None of these changes were observed in the tails of the mTBI mice 
For both tissues, the positive dye signal appears to be larger than the 
extravasation seen microscopically, probably due to the increased sensitivity to 
damage using Evans’ blue dye compared to H&E stained sections (79). 
Quantification of the dye intensity shows that the injury is isolated to the targeted 
tissue (Fig 6C&F). The combination of the near-infrared quantification and 
histological observations indicate the specificity of trauma between these models 
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Figure 2-6. Evaluation of trauma localization.  
Trauma is limited to the injured region by histological analysis and Evans’ blue 
quantification. (A) Near-infrared imaging of fixed brain slices shows an intense signal 
in mTBI (right) but not tail trauma mice (left), where it is limited to the vasculature. (B) 
H&E staining of histologic section confirms localization of damage. (C) Quantification 
of albumin extravasation by near-infrared scans confirms that mTBI mice have 
higher signals across the measured sections. (D) Near-infrared imaging indicates 
presence of Evans’ blue leakage of TT mice (left) while mTBI mice (right) have 
intensities limited to vascular regions. (E) H&E sections confirm localization of 
damage in the tail (F) Quantification of Evans’ blue fluorescence shows increased 
signal in the tails of TT mice. (C, F) Data shown as mean±SEM. (n=4 per group). 
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Mild Traumatic Brain Injury Specifically Enhances Resistance to Pneumonia 
Since both trauma groups induced similar physiologic and hematologic 
responses that normalized by 24h, we proceeded to study whether only mTBI 
induces pulmonary immune priming to help eradicate pathogens. Each trauma 
group was challenged 48h after injury with 0.5-1.0x108 CFUs of Pseudomonas 
aeruginosa intratracheally using a well described non-surgical model (11, 101). 
mTBI mice exhibit significantly improved 7 day survival compared to TT mice 
(76.5% vs 40%, Figure 7A). In fact, TT mice survived at a rate similar to sham 
mice, and thus in future experiments the sham group wa omitted following 
ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments) to 
reduce the number of mice used. TT or mTBI mice were challenged with 
Pseudomonas 48 hours after trauma and BAL performed at 4h post-infection. An 
enhanced pulmonary response to the pathogen was mTBI specific with a four-
fold increased neutrophil recruitment to the airspaces compared to TT (Fig. 7B). 
mTBI mice also have significantly reduced bacterial numbers in the alveolar 
spaces (Fig. 7C). Early neutrophil recruitment has been previously shown to be a 
key determinant of outcomes in serious infections (40). Coagulation parameters 
were measured at 18h following Pseudomonas pneumonia. D-dimer, a product of 
fibrin clot degradation, was significantly elevated in mTBI compared to TT mice. 
This may be an indication of reduced coagulopathy in mice as it shows that mTBI 
mice are able to break clots down effectively, but further investigation will be 
needed to elucidate differences in the coagulation cascade. This improved 
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recruitment and diminished bacterial burden found in mTBI mice is reflected in 
their improved survival. The enhanced neutrophil recruitment and bacterial 
elimination warranted further studies to elucidate the specific mechanism(s) by 
which mTBI reduces bacterial burden.  
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Figure 2-7. Response to pulmonary pathogen challenge after TT or mTBI. 
 (A) mTBI mice survive at higher rates than either sham injury or tail trauma mice to 
a Pseudomonas pneumonia challenge (76.5% vs 33%/40%, n=17, 6, 20 
respectively). (B) At 4h post-pneumonia, mTBI mice recruit significantly more 
neutrophils to the airspace compared to tail trauma. (C) mTBI mice have 
significantly reduced bacterial burdens in the bronchoalveolar lavage (BAL) fluid  
(D) Serum fibrinogen levels differ between no trauma and either trauma group. (E) 
No significant differences between PAI-1 levels. (F) Only mTBI levels have 
increased D-dimer following pulmonary challenge. Data shown as mean±SEM.  
*p<0.05, ***p<0.001, ****p<0.0001 between TT or mTBI or groups as indicated. 
Data for (D-F) were collected by Evan Catudal of the Kurosawa Lab 
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Substance P signaling is crucial to the enhanced resistance to pneumonia  
SP signaling is known to improve neutrophil chemotaxis, cytokine 
production, and ROS generation (4, 178, 182). Our previous work demonstrated 
the critical role of substance P in mTBI priming of the host response where 
antagonism of the primary substance P receptor, neurokinin 1 (NK-1R), 
abrogated the mTBI survival benefit (209). Our hypothesis is that mTBI causes 
rapid release of SP to increase the host response to a pulmonary pathogen. BAL 
was collected 30 and 120 minutes after trauma for SP measurements by 
competitive ELISA, Within 30 minutes, SP was elevated and returned to baseline 
within 120 minutes (Figure 8).  
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Figure 2-8. Measurement of SP following mTBI.  
SP rises in both BAL and plasma at early time points following injury. Mice 
were sacrificed at the time points indicated and SP measured by competitive 
binding ELISA. Data shown as mean±SEM. n = 3 per group 
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The SP antagonist used in the original manuscript is no longer available 
(209). However a different NK-1R antagonist, aprepitant, is an FDA-approved 
drug for chemotherapy induced nausea/vomiting (CINV). Since SP was induced 
so rapidly, aprepitant was administered by oral gavage 2h prior to trauma and 
every 12h until 1h prior to pneumonia instillation. Administration prior to trauma 
and through the post-trauma period was chosen to negate potential effects of SP 
release following the injury. NK-1R blockade with aprepitant eliminated the 
survival benefit of mTBI (Fig7), supporting our previous findings. Aprepitant 
treatment did not alter survival of TT mice. mTBI + vehicle mice had significantly 
less mortality than the other groups. These studies confirm that SP signaling is a 
specific and critical mechanism in the enhanced host response found in our mTBI 
model.  
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Figure 2-9. Substance P modulation of TBI + Psd mortality. 
Blockade of substance P signaling abrogates survival benefit seen in mTBI 
mice. Aprepitant was administered 2h prior to trauma, and every 12h up until 
1h prior to pneumonia. Mice were monitored for 14d, no deaths occurred after 
7 days. Survival curves were analyzed by log-rank (Mantel-Cox) test. *p<0.05 
compared to mTBI+aprepitant 
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Discussion 
Severe TBIs are a prevalent problem with approximately 2.5 million TBI-
related emergency department visits, hospitalizations, or deaths in the United 
States each year. In the current study we investigated a poorly understood 
protective mechanism following mild TBI (26). Our focus is on mild traumatic 
brain injuries as these patients do not have immediate neurological sequelae, but 
actually exhibit enhanced resistance to pneumonia (209). Our mTBI model is 
designed to investigate insights into the neuroimmune axis to develop new host-
driven therapies to fight pathogens. Interestingly, our previous work showed that 
mTBI enhances the resistance to pneumonia compared to sham injured mice. 
However, valid concerns about the effect of any trauma on immunity were raised 
as the clinical comparison used injury-severity matched, non-head trauma 
patients. The goal of this study was to generate a suitable control trauma model 
to answer whether immune priming is specific to mTBI. We propose that our tail 
trauma model accomplishes this goal by inducing similar early responses 
following trauma, isolating the site of injury, and returning to normal by 24h. 
These results show that only mTBI increases bacterial clearance, neutrophil 
recruitment, and survival compared to tail trauma. This tail trauma model will 
serve as an appropriate control for future studies investigating the mechanisms 
of immune augmentation. Furthermore, the use of this model is clinically relevant 
as studies would compare TBI patients to blunt, non-head trauma patients of 
similar injury severity instead of healthy subjects. By accounting for potential 
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confounding variables in pre-clinical models, we hope to improve translation of 
our research to patients. Thus, having a proper control model is important to 
determine specific mechanisms by which our mTBI model can enhance immune 
responses.  
Although immune modulation is not a novel idea, major discoveries in 
dampening its response have garnered most of the attention. Enhancing its 
function is now coming to the forefront as a potential method to combat antibiotic 
resistance. Resistant organisms are becoming an increasingly difficult problem to 
overcome. These pathogens are estimated to cause 23,000 deaths in the United 
States and $20 billion in excess healthcare costs per year (24). Recently, the 
United States government doubled its budget for combating antibiotic resistance 
to $1.2 billion dollars to combat this epidemic. The explosion of antibiotic 
resistant organisms coupled with the slow generation of effective new antibiotics 
requires development of new strategies to combat these pathogens. Our current 
pharmacological arsenal may be ineffective against resistant pathogens, but prior 
evidence shows the pathogens may still be susceptible to host defenses (45, 
134). Pathogens themselves may alter innate immune responses as a result of 
modifications acquired alongside resistance (192). Host defenses, especially 
neutrophils, play an important role as the front-line of containment and resolution 
of infections. Thus, augmenting innate immune responses may provide an 
effective alternative to antibiotics. Our mTBI model, and TT control, will allow 
further investigation into pathways to be exploited for neuroimmune modulation. 
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These results confirm our previous work that substance P is a critical 
mediator of immune priming following mTBI using a different NK-1R inhibitor. 
Aprepitant, an FDA-approved NK-1R antagonist for chemotherapy-induced 
nausea/vomiting (CINV), similarly eliminated the enhanced resistance against 
pneumonia found in mTBI mice. While effective against CINV, aprepitant 
treatment could potentially endanger patients by further blunting their already dull 
immune responses, as suggested in previous clinical trials (51). We hypothesize 
that mTBI initiates vagal signaling to release SP that leads to primed host 
responses to microbial infections. SP signaling has been previously shown to 
have numerous positive effects on immune cells, such as increased chemotaxis, 
phagocytosis, and reactive oxygen species production (4, 178, 182). Further 
investigation is necessary to determine the precise role of SP in enhancing 
innate immunity, as well as potential vagal cholinergic activation, in our model. 
Despite the physiologic similarities between the models prior to infection, only 
mTBI provides protection against an infectious challenge. Thus, our tail trauma 
model will serve as an appropriate mild trauma control for future studies into the 
mechanism of neuroimmune priming found in our mTBI model.  
These results show that tail trauma can serve as an excellent mild trauma 
control model. We then demonstrate that mTBI specifically augments the innate 
immune response to pneumonia compared to tail trauma, which agrees with our 
previous clinical study. This model allows us to study the specific mechanism(s) 
of mTBI augmenting the innate immune response. We anticipate that 
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immunological insights elucidated from these models will allow for the 
development of new host-driven therapies to combat infections.  
 
.
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Chapter 3: Substance P Signaling Improves Neutrophil Recruitment and 
Function 
 
Introduction  
Substance P, first discovered in 1931 and characterized in 1971, is classically 
known as a pain signal. It is an eleven amino acid peptide formed from a 
precursor preprotachykinin A (PPT-A) encoded by the TAC1 gene. SP 
preferentially binds to the NK1R, but it can bind to the other tachykinin receptors, 
NK2 and NK3, with much less affinity (145). Substance P has been shown to be 
released following TBI that is related to the severity of the injury (122, 216). It is 
thought that this signaling leads to further neuronal damage. In a rat model of 
TBI, antagonism of NK1R was able to reduce motor and cognitive deficits. SP 
antagonist n-acetyl-L-tryptophan (NAT) treated rats showed significantly longer 
times on a rotatod test and recovered to normal levels within 3 days, whereas 
vehicle TBI rats still showed significant deficits at 7 days. In addition, NAT 
treatment reduced the number of injured axons (38, 49). On the other hand, SP 
has been previously shown to modulate neutrophil functions and our recent work 
has shown its key role in enhanced resistance to pneumonia following TBI (209).  
Neurokinin receptors are expressed widely throughout tissues and thus 
SP release can have various effects. SP acting on the endothelium can cause 
vasodilation (210), which may have beneficial effects by slowing circulation as 
well as allowing easier passage of neutrophils across the endothelium. Enhanced 
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endothelial ICAM-1 expression by SP pretreatment has been shown to improve 
neutrophil transmigration (139). SP can also alter pro-inflammatory cytokine 
production, as blockade has previously been shown to reduce TNFα production 
(48). Recent work has shown that SP exposure enhances the production of IL-17 
of human preadipocytes (170). SP has also been shown to be a cause of tissue 
injury following trauma by upregulating pro-inflammatory cytokines and 
chemotactic factors (172). Mice deficient in preprotachykinin-A (PPT-A-/-), the 
gene that encodes SP, were protected from pulmonary damage in an acute lung 
injury (ALI) model induced by burn model. This effect was reversed by the 
administration of SP to those mice (171). This evidence in disease states points 
to SP signaling as a deleterious mechanism, but other work has shown 
enhanced neutrophil functions.  
Early research showed that SP could enhance neutrophil respiratory burst 
when measured using chemliluminescent substrates (16, 36). Helme et al. 
showed that SP was able to induce neutrophil chemotaxis at high concentrations 
of 5x10-5M using a Boyden chamber. Filling both chambers with SP to test for 
chemokinesis did not show any difference from controls. (85). SP itself can 
enhance neutrophil chemotaxis through upregulation of chemokine receptors 
CCR1 and CXCR2. In addition, SP treatment increased neutrophil production of 
chemotactic factors macrophage inflammatory protein (MIP-1α) and MIP-2, which 
would attract more neutrophils to the site of infection. This increase is mediated 
through nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) as 
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inhibitors of NF-κB blocked activity (182). SP can also enhance neutrophil 
cytotoxic ability against opsonized cell targets in a dose-dependent manner and 
production of chemokines, LTB4 and 5-HETE. This work also showed that formyl-
Met-Leu-Phe (fMLP) stimulated superoxide production was significantly 
increased after SP priming (208). SP treatment was also shown to enhance 
human PMN adherence to and migration across cultured endothelial cell layers 
(21, 46, 218). When primed with SP, human PMNs displayed enhanced Ca2+ flux 
in response to IL-8 stimulation. SP itself did not cause Ca2+ entry into the cell, 
displaying that it primes, but does not activate neutrophils (47). This was similar 
to earlier findings, that increased neutrophil recruitment does not happen in a 
carrageenin air pocket model without the presence of a inflammatory stimulus 
(20). Another study showed that SP primed fMLP-induced calcium influx, but it 
does not directly activate ROS production measured by chemiluminescence (20, 
76). 
 Work in our mTBI model has previously shown that SP is a key 
component of the enhanced resistance to pneumonia. Blockade of SP signaling 
decreased both PMN recruitment and bacterial clearance. Further investigation 
to determine the specific mechanism by which mTBI enhances the innate 
immune response was warranted. These studies focused on the role of SP in the 
context of neutrophil functions. These experiments show that improved 
chemotaxis can be induced by an exogenous chemokine instead of an infectious 
stimulus. In addition, neutrophil microbicidal capacity of neutrophils is enhanced 
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by SP priming. Experiments into neutrophil intracellular mechanisms of killing do 
not show significant differences between TT and mTBI mice. However, 
neutrophils from mTBI mice generate significantly more NETs in response to 
bacterial challenge. Using human whole blood, we demonstrate that an NK1R 
agonist augments phagocyte killing of Pseudomonas aeruginosa.  
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Materials and Methods 
 
NK1R Agonism/Antagonism 
Mice were administered the NK1R agonist GR73632 (0.5mg/kg) by 
intraperitoneal injection (i.p.) every 12 hours immediately following trauma. The 
NK1R antagonist, aprepitant was administered as described in chapter 2. 
Another NK1R antagonist, CJ-12,255 (25mg/kg Pfizer), was administered by i.p. 
injection every 12 hours beginning 1h prior to trauma. MouseOx data was 
obtained as described previously at the time points indicated.  
 
Mouse model 
mTBI and tail trauma were induced as described in the previous chapter. Sham 
mice were given anesthesia followed by a mock TBI. Sham mice were included 
as some studies were done prior to IACUC approval of the tail trauma model. 
Sham and tail trauma groups were combined as appropriate after comparison of 
the sham and tail trauma data.  
 
Chemokine Recruitment 
48h after sham injury, tail trauma, or TBI, 500ng of recombinant murine KC 
(Peprotech) in 25uL of saline was intratracheally administered. 4h after 
instillation, mice were sacrificed and BAL performed for cell counts and cell 
differential as previously described. Data was analyzed by one-way ANOVA with 
Sidak’s post-tests.  
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CXCR2 Measurement 
Bone marrow was flushed from femur and tibia of mice 48h after trauma using 
10mL of PBS-Heparin (10U/mL) then spun at 450g for 10 min. The supernatant 
was aspirated and the pellet was broken up by gentle agitation. Hypotonic lysis 
was performed using 1mL H2O for 10 seconds followed by 1mL 1.8% NaCl. 3mL 
of HBSS was added to wash the cells before centrifugation at 450g for 10 min. 
The remaining pellet was resuspended in 1mL HBSS and counted using a 
coulter particle counter as described earlier. 106 cells was taken from each 
sample. After 15 min incubation with Fc-block, samples were stained with α-Ly6G 
(1:500), α-CXCR2 (1:100), and α-GR-1(1:500) antibodies for 30 min. Samples 
were analyzed on a BD FACS Calibur machine. Gating identified GR-1+Ly6G+ 
populations as neutrophils and geometric mean fluorescence intensity was 
reported.   
 
Killing Assay 
Blood Bacterial Killing Assay 
Peripheral blood was obtained by retroorbital exsanguination of mice under 
isoflurane anesthesia into 100uL of heparin. 20uL was collected simultaneously 
for hemavet analysis. Peripheral blood was spun down at 1000g for 5 min and 
the plasma removed. The Hemavet neutrophil count was doubled to account for 
the reduced volume and the volume necessary for 2x105 neutrophils was 
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calculated. All volumes were normalized between samples to 190uL prior to 
adding bacteria.  
 
Bone Marrow Bacterial Killing Assay 
Both tibia and femurs were removed by blunt dissection and flushed with a total 
of 10mL of HBSS-EDTA (15mM) + 1% BSA. These samples were spun at 450g 
for 8min, resuspended in 1mL of HBSS and overlaid over a 2mL of 62.5% 
PerColl. These were centrifuged at 1500g for 30 minutes with no brake. After 
centrifugation, all but the pellet was aspirated and resuspended 3mL of HBSS for 
washing. These cells were then spun at 400g for 8 minutes at 4C, then a 
hypotonic lysis was performed on the pellet. After the lysis, cells were counted on 
a Beckman Coulter particle counter and the volume required for 5x105 
neutrophils was calculated. Cytospins were also prepared from each sample to 
ensure efficient separation.  
 
Bacterial killing assay samples were combined with a multiplicity of infection 
(MOI) of 5 to the cell count for 1h with gentle mixing. Two samples with no cells 
were incubated alongside to provide a control. After 1h, 100uL was incubated in 
H2O to lyse the murine cells and then serial dilutions were made in HBSS onto 
blood agar plates. Killing percentage was calculated as % = (CFUbac – 
CFUsample)/CFUbac x 100.  
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Triple Labeled Bacterial Killing Assay 
Bacterial Labeling – E. coli (strain HB101) at OD 0.5-0.8 in tryptic soy broth were 
pelleted at max speed for 10 minutes. The pellet was washed twice with 30mL 
PBS. At the end of the second wash, E.coli were resuspended in 3mL of PBS 
and heat inactivated at 80°C for 30 minutes. 1x1010 CFU of bacteria were 
separated into a 15mL conical tube and washed with N2 purged PBS. This wash 
was repeated twice and the bacteria were finally resuspended at a concentration 
of 1x1010 CFU/mL in a 3mL reactivial (Sigma). 12.5μL Oxysens (50mM) were 
used per mL of bacteria while vortexing gently. Air was removed from the vial 
and the bacteria were rotated end over end for 1h at room temperature. 10μL of 
pHrodo-SE (50mM) per mL of bacteria were added in a similar fashion and then 
rotated end over end for 30 minutes. Then, 3.5μL of Alexafluor-350 SE per mL of 
bacteria were added in a similar fashion. Bacteria were then rotated end over 
end for 2h and then overnight at 4°C. The next day, bacteria were washed three 
times and resuspended to 1x1010  CFU/mL and stored under N2 at 4°C. Labeled 
bacteria were opsonized with antibodies against E.coli serotypes O+K (Pierce) at 
a 1:10 (antibody:bacteria) ratio for 20 min at room temperature while being 
rotated end over end. 800μL of HBSS w/Ca2+/Mg2++1% BSA was added. 
Bacteria were then spun for 7 minutes at 2900g. The supernatant was aspirated 
and pellet resuspended to approximately OD = 0.200. (32) 
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In vivo bacterial killing studies 
Intratracheal instillation of 5x107 triple labeled bacteria followed by BAL at 4h was 
performed as described above. BAL fluid was spun at 450g for 8 min, a 
hypotonic lysis performed, then cells were analyzed by flow cytometry on a BD 
LSRII. Peripheral blood was obtained by retroorbital exsanguination into 100uL of 
heparin (1000U/mL). 23μL of peripheral blood was incubated with 2μL of labeled 
bacteria at a dilution of 1:16 for 30 min at 37°C under gentle magnetic stirring. 
After incubation, the magnet was removed and 600uL of RBC lysis buffer was 
added for 6 minutes with brief vortexing every 2 minutes. 24uL of 25X PBS was 
added to quench the reaction and an underlay of 200uL of 20% percoll was 
added. Samples were spun for 10 min at 1000g. The supernatant was aspirated 
and the pellet resuspended in 100μL PBS. 20μL of 1% brilliant black solution was 
added to each sample prior to analysis on the LSRII. Bone marrow neutrophils 
were omitted from the studies due to technical difficulties. Data was analyzed by 
FlowJo (TreeStar) with a gating strategy to isolate PMNs and phagocytosis 
positive events.  
 
Neutrophil Extracellular Trap (NET) Assay 
Neutrophils were isolated from bone marrow as previously described. 2x105 
neutrophils in a final volume of 200uL were added into each well of a black, clear 
bottom, fluorescent plate. Peripheral blood underwent two hypotonic lysis steps, 
once into 11mL of H2O and rescued with 10X HBSS followed by a wash in 3mL 
  
67 
HBSS. The second hypotonic lysis was 1mL of H2O followed by 1mL 1.8% NaCl. 
Using hemavet values, each sample was resuspended in 200uL and volume 
needed for 2x105 neutrophils was calculated. Samples were left alone or in the 
presence of 1x106 CFU of opsonized Pseudomonas aeruginosa. The plate was 
spun for 6min at 200g, then incubated for 45min at 37°C, shaking at 100RPM. At 
45min, 2uL of Sytox Blue (Invitrogen, Carlsbad CA) was added for a final 
concentration of 2.5μM into each well. Other samples were treated with 1uL of 
100mg/mL DNAse I, or 10% Triton X-100, as applicable. The plate was 
incubated for 15min at 37°C with 100RPM shaking for 15 minutes. The plate was 
read on a Tecan Infinite M1000 Pro at excitation/emission of 444/480 (maxima 
for Sytox Blue) with optimal gain and bottom read. Data was taken in duplicate 
for bacteria incubated samples (BIS) and reported as the BIS-DNAse sample 
with normalization using mean bacteria signal between runs (150). Data was 
analyzed by one-way t-test, based on results from bacterial killing assays. 
 
Survival 
48h after sham injury or TBI, 5x107 CFU of Pseudomonas aeruginosa was 
instilled as previously described in chapter 2. Mice were observed every 12h for 
mortality. Survival data was analyzed by log-rank (Mantel-Cox) test.  
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Human neutrophil ex vivo killing and NK1R agonist treatments 
Whole blood from one human donor was incubated with 1x107 CFU of 
Pseudomonas aeruginosa at 37°C for 4h. NK1R agonist was added 5 minutes 
prior to incubation with bacteria. Remaining bacteria were quantified by serial 
dilutions onto the sheep’s blood agar plates. A separate sample was incubated 
with varying doses of NK1R agonist, GR73632, to test the effect of SP signaling 
alone on cytokine production. NK1R agonist alone was given to separate 
samples for 4h in whole blood and plasma was collected after centrifugation at 
1000g for 5 min. TNFα and IL-8 production were measured by sandwich ELISA 
with matched antibody pairs.  
 
Data Analysis 
Data was analyzed using Prism 6.0 (GraphPad). For experiments with more than 
two groups, one-way ANOVA with the appropriate post-tests between applicable 
groups was performed. Experiments between two groups were analyzed using a 
student’s t-test. Survival curves were analyzed by log-rank (Mantel-Cox) test.
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Results 
NK1R Agonist and Antagonist Treatments 
SP induces widespread vasodilation that allowed us to measure the efficacy of 
our NK1R pharmacological manipulations. Using cervical collar telemetry, 
vasodilation can be seen as drops in pulse distension, a measure of changes in 
local vessel volume due to local blood pressure changes. Saline alone injection 
did not change pulse distension over time (Fig. 1, black). SP injection, which 
causes vasodilation, induced a rapid, transient decrease in pulse distension (Fig 
1, red). Administration of the NK1R agonist, which should mimic SP’s actions, 
elicited a similar vasodilation and drop pulse distension, but was sustained over a 
longer period (Fig 1, orange). Pretreatment with aprepitant, a NK1R antagonist, 
eliminates the vasodilatory response in mice when the NK1R agonist was 
administered (Fig 1, blue). These results show that our pharmacological 
manipulations have a physiologic effect in our mice.  
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Figure 3-1. Measurement of SP response by cervical collar telemetry.  
SP and NK1R agonist administration both induced a rapid decrease in pulse 
distension that was blocked by aprepitant. Mice were injected i.p. with saline, 
substance P, or NK1R agonist GR73632 (0.5mg/kg). Aprepitant was 
administered p.o. 2h prior to challenge with NK1R agonist GR73632. Area 
under the curve (AUC) for 5 min shows significant decrease by SP and 
GR73632. Data was analyzed by one-way ANOVA with Dunnett’s post-test 
against saline injected group. **p<0.01, ****p<0.0001 
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KC Chemokine Recruitment of Neutrophils 
Neutrophils respond to chemokines by migrating towards the source of the 
gradient. Past studies have shown SP enhances PMN chemotaxis by 
upregulated chemokine receptors or changes in calcium flux (47, 182). We 
hypothesized that SP is responsible for the enhanced recruitment to the lungs 
during bacterial pneumonia. To determine this, recombinant murine KC (CXCL1) 
was administered intratracheally to mimic local production of a chemokine and 
test whether this effect is specific to Pseudomonas aeruginosa infection. Mice 
were randomized into sham/tail injury, sham/tail with NK1R agonist, mTBI, or 
mTBI with NK1R antagonist. 48h after trauma, recombinant murine KC was 
instilled i.t.. Mice were sacrificed at 4h and BAL performed to quantify cell counts 
and obtain a differential.  
 mTBI mice recruit significantly more neutrophils to the alveolar space 
compared to sham/tail injured mice. Blocking NK1R signaling eliminated this 
effect in mTBI mice, while NK1R agonism was able to enhance recruitment (Fig 
2). These results show that increased recruitment to chemokines is dependent 
on NK1R signaling. In addition, the improved response to a host chemokine 
suggests that this effect is not pathogen specific, but could be generalized 
response able to be exploited for use against other microbes.  
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CXCR2 Expression on Bone Marrow Neutrophils 
Previous studies demonstrated that SP induces increased production of both CC 
and CXC chemokine receptors CCR-1 and CXCR-2 (182). KC, or CXCL1, 
signals through the CXCR2 receptor. As such, we investigated the expression of 
this receptor on the surface of bone marrow neutrophils by flow cytometry. No 
significant differences were found in the geometric mean fluorescence intensity 
(MFI) between groups in Gr-1+Ly6G+ neutrophils. Interestingly, sham mice 
appear to trend toward increased CXCR2 expression, but recruit significantly less 
neutrophils, as seen in Figure 3.  
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Figure 3-2. Neutrophils recruited by KC chemokine treatment. 
4h after KC instillation, mTBI and NK1R agonist treatment recruit significantly 
more neutrophils to the airspace than sham or mTBI+NK1R antagonist treated 
mice. Data shown as mean±SEM, analyzed by one-way ANOVA with Sidak’s 
multiple comparisons test between groups indicated **p<0.01, ***p<0.001 
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Bacterial Killing Assays 
mTBI mice have consistently shown increased PMN recruitment and reduced 
bacterial burdens in the lung, as previously published against sham injury and as 
described above compared to tail trauma mice. Lower bacterial burden could be 
simply due to a mass effect of increased neutrophils in the airspace or enhanced 
microbicidal activity, or a combination of both. To investigate this, we used a 
bacterial killing assay. Whole blood or isolated neutrophils were incubated with 
Pseudomonas at an MOI of 5. Neutrophils isolated either from blood or bone 
marrow from mTBI mice killed more bacteria than sham/tail injury mice. 
Furthermore, this effect was SP signaling dependent as neutrophils from mTBI + 
NK1R antagonist treated mice displayed significantly less killing than mTBI and 
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Figure 3-3. CXCR2 expression on the surface of bone marrow neutrophils. 
No significant differences were found between groups. gMFI was quantified 
for a GR-1+Ly6G population. Data shown as mean±SEM and analyzed by 
one-way ANOVA with Sidak’s post- test.  
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were similar to sham/tail injury mice. NK1R agonism was able to enhance the 
bactericidal activity of these neutrophils (Fig. 4). These data indicate that 
neutrophils are primed in a NK1R dependent manner for both enhanced 
recruitment and microbial killing. In addition, this suggests that priming effects 
extend into the bone marrow  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B o n e  M a r r o w
T a il/S h a m T a il/S h a m
 +  N K 1 R  A g o n is t
m T B I m T B I
 +  N K 1 R  a n ta g o n is t
0
1 0
2 0
3 0
4 0
5 0
K
i
ll
i
n
g
 %
*
*
*
P e r ip h e r a l  B lo o d
T a il T a il
 +  N K 1 R  A g o n is t
m T B I m T B I
 +  N K 1 R  a n ta g o n is t
0
1 0
2 0
3 0
4 0
5 0
%
 
K
i
ll
i
n
g
****
***
*
 
Figure 3-4. Pseudomonas aeruginosa killing by neutrophils. 
Enhanced neutrophil function is mediated by SP signaling. 2x105 neutrophils 
from plasma-free blood or purified from bone marrow were incubated with 
Pseudomonas at an MOI of 5 for 1h prior to serial dilutions on blood agar 
plates. Killing was calculated from a sample incubated without cells. Data 
reported as mean±SEM. Data was analyzed by one-way ANOVA with Sidak’s 
post-test. *p<0.05, ***p<0.001, ****p<0.0001 
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Triple Labeled Bacteria Uptake Assay 
To investigate the increased bactericidal activity of primed neutrophils, we used a 
triple labeled bacterial uptake assay. Heat-killed E.coli were labeled with pH/ROS 
insensitive, ROS-only sensitive, and pH-only sensitive probes. Intracellular killing 
of neutrophils by microbes requires the ingestion of the target, reported by the 
pH/ROS insensitive probe. Production of ROS and acidification of the lysosome 
are reported by the two other probes, respectively. Incubation of the bacteria with 
cells allows us to determine these mechanisms of intracellular killing by flow 
cytometry analysis. Our gating strategy (Fig. 5) allows us to determine several 
factors of intracellular killing. ROS production and pH changes are normalized to 
the amount of bacteria ingested, then to the signal of bacteria to eliminate inter-
experiment variability. ROS production and pH changes are first normalized to 
the amount of bacteria ingested, as differences in the number of bacteria per cell 
would confound these measurements. For example, if more bacteria were 
ingested that subsequently induced more ROS, we might mistake this for 
enhanced peak ROS generation, but it is due to ingestion of extra bacteria. 
Phagocytosis % is defined as the % of the cells that are phagocytosis+ divided 
by the total number of cells that can phagocytose. Bacterial uptake is normalized 
as the MFI of pH/ROS insensitive probe divided by MFI of bacteria.  
 
Pulmonary neutrophils isolated from TT or mTBI mice 4h after instillation did not 
differ in any of the parameters analyzed (Fig 6.). These may be due to 
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differences between a live Pseudomonas infection compared to a heat-killed 
E.coli challenge. As neutrophils from blood or bone marrow demonstrated ex vivo 
enhanced killing, we sought to analyze their functions using the triple labeled 
bacteria uptake assay.  Neutrophils from the plasma-depleted blood of mTBI and 
tail trauma mice, and their respective receptor manipulations, were analyzed 
using triple-labeled bacteria. Bone marrow neutrophils from mice were excluded 
due to technical difficulties. A low dose and a saturating dose of bacteria were 
used to determine whether neutrophils displayed differences in peak functions 
measured. Lower, unsaturating doses allows for better discrimination in the 
production of ROS or pH changes per bacteria. Saturating doses are better at 
discriminating peak bacterial uptake. No significant differences were seen 
between mTBI or tail trauma mice (Fig. 7). However, mTBI treated with 
antagonist had significantly reduced ROS indices compared to mTBI (Fig.7b). On 
the other hand, this is not reflected by an increase between TT mice and TT mice 
primed with NK1R agonist. NK1R agonist treatment did, however, increase the 
acidification of phagosomes in cells, which was not seen in any other group (Fig 
7c). At saturating doses, neutrophils from mTBI mice or TT with NK1R trended 
toward increased number of bacteria taken up per cell. These data suggest that 
mTBI priming of neutrophils through substance P does not appear to alter ROS 
production or acidification of lysosomes. Thus, these particular intracellular killing 
mechanisms may not be the mechanism by which SP enhances bacterial killing. 
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Figure 3-5. Gating strategy for triple labeled bacteria uptake assay.  
Samples are gated for cells able to phagocytose (PhagoE), then for single 
cells. Phagocytosis+ was gated for based on the signal of non-pH/non-ROS 
sensitive probe. Data was analyzed as phagocytosis %, or 
ROS/acidification/uptake normalized to number of bacteria ingested. 
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Figure 3-6. Pulmonary triple labeled bacterial uptake assay.  
No significant differences in neutrophil functions were found between groups. 
Bacteria were instilled i.t. and BAL cells were obtained at 4h. Data presented 
as mean±SEM. Data was analyzed by student’s t-test.  
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Figure 3-7. Triple labeled bacteria uptake by peripheral blood.  
(A) No differences were found in Phago% (B) mTBI + aprepitant exhibited 
significantly reduced ROS index compared to mTBI. (C) TT + NK1R agonism 
increased acidification index compared to TT mice.  (D) No significant differences in 
bacterial uptake between groups. Data presented as mean±SEM and analyzed by 
one-way ANOVA with Sidak’s post-test. * p<0.05, **p<0.01, ***p<0.001 between 
groups indicated. Low dose assays discriminate in ROS and phagosome differences 
while saturating doses discern differences in peak bacterial uptake.  
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NET Formation  
NETs are a recently described phenomenon where neutrophils expunge their 
contents to form a web comprised of antimicrobial proteins, enzymes, and DNA 
that serves to kill pathogens and limit their spread. NETs allow for bacterial 
trapping in a much larger area and prevent bacterial dissemination. In addition, 
they have anti-microbial activity against a wide variety of pathogens, from 
bacteria to viruses (212). 2x105 neutrophils were prepared from either blood or 
bone marrow, and then incubated with an MOI of 5 of Pseudomonas for 1h total. 
Extracellular DNA as a surrogate for NET formation was quantified by measuring 
the fluorescence intensity of a cell-impermeant DNA-binding dye, Sytox Blue. 
mTBI neutrophils from either source produced significantly more NETs than tail 
trauma mice. These data suggest that enhanced killing by mTBI mice may be 
mediated by increased production of NETs, but further experimentation into SP’s 
impact is necessary.  
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Figure 3-8. NET formation by neutrophils stimulated with Pseudomonas.  
(A) Neutrophils from bone marrow or peripheral blood of mTBI mice have increased 
NET formation following bacterial stimulation compared to TT mice. (B) No 
significant differences were found between mTBI and mTBI + NK1R antagonist 
treated mice. (C) No significant differences were found between TT and TT+NK1R 
agonist mice, although NK1R agonism trends toward improved NET formation. Data 
presented as mean±SEM and analyzed with one-tailed t-test. *p<0.05 
  
82 
NK1R Agonism on Survival 
To test whether SP priming of innate immunity could improve outcomes, mortality 
was followed for NK1R agonist treated mice in our pneumonia model compared 
to sham+vehicle or mTBI mice. NK1R agonism did not improve survival 
compared to sham+vehicle mice. SP signaling alone may produce unchecked 
neutrophil recruitment or activation inside the airspace that results in lung 
damage. These results suggest that a second pathway is involved that limits 
inflammation, reflected by reduced chemokine and pro-inflammatory cytokine 
production in our model (209).  
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Figure 3-9. NK1R agonist treatment effect on survival.  
NK1R agonist treatment did not improve survival compared to sham mice. Mice 
were challenged with 0.5-1.0x108 CFU of Pseudomonas 48h after. NK1R agonist 
was administered every 12h until Pseudomonas challenge. Both sham and sham + 
NK1R agonist have significantly less survival compared to mTBI mice.  Data 
analyzed by log-rank (Mantel-Cox) test ***p<0.001, ****p<0.0001 compared to mTBI 
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Substance P signaling enhances human phagocyte function 
To test whether SP signaling could improve phagocyte function in humans, we 
tested the ex vivo effects of NK1R on human whole blood. Venous blood was 
obtained with consent from one donor. First, we tested whether SP signaling 
alone stimulates pro-inflammatory cytokine production from whole blood by 
adding the NK1R agonist for 4h. Plasma cytokine production was similar at all 
doses of agonist given (Fig 10a). Next, we tested whether NK1R agonism has 
deleterious effects on Pseudomonas survival. However, 4h incubation with 
GR73632 slightly increased bacteria recovered (Fig 10b). Thus, increases in 
whole blood killing should be attributed to improved phagocyte function. Human 
whole blood demonstrated enhanced killing in a dose dependent manner to 
NK1R stimulation (Fig 10c). While the data is obtained from one donor, these 
results are promising for clinical applications.  
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Figure 3-10. Effect of NK1R stimulation on human whole blood killing.  
NK1R agonist improves phagocyte function in a human whole blood killing 
assay. (A) NK1R agonism alone did not stimulate pro-inflammatory cytokine 
production after 4h. (B) NK1R agonist without any blood did not display 
bactericidal activity on Pseudomonas at 4h. (C) Phagocyte killing of 
Pseudomonas is augmented in a dose-dependent fashion by NK1R agonism. 
Data is from one human donor.  
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Discussion 
SP has been considered a deleterious factor in many studies of trauma 
and injury models, contributing to further inflammation and damage (137). A 
recent multicenter prospective observational study measured serum SP levels of 
severe TBI patients on the day of admission. Higher initial serum SP levels were 
found in the nonsurvivng cohort compared to survivors. In addition, a negative 
associated was found between serum SP level and GCS score on presentation 
(122). However, these experiments show a clear benefit to SP signaling against 
an infectious challenge. Enhanced chemotaxis and microbicidal capacity of 
neutrophils was modulated through manipulations of the NK1R, displaying the 
critical role of SP. In addition, mTBI mice displayed increased production of NETs 
in response to bacteria. Based on these findings, we propose a mechanism by 
which mTBI induces SP release to augment neutrophil recruitment and pathogen 
elimination, through NET formation.  
These studies show promise for NK1R agonism to be translated into use 
to fight microbial infections. Since instillation of a host chemokine was able to 
recapitulate enhanced recruitment effects in Pseudomonas pneumonia, it 
suggests improved responses could be generalized towards other pathogens. 
Further work in different models of infection, especially those utilizing antibiotic 
resistance strains is warranted. Previous work in SP priming showed that 
enhanced migration of neutrophils is specific for chemotaxis, not chemokinesis 
(85). Furthermore, SP treatment does not activate neutrophils to respond by 
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itself. Cao et al. used a carrageenin air pouch model of inflammation to show that 
SP administration alone did not induce neutrophil recruitment over control. 
However, once administered with IL-1β, SP significantly increased the number of 
neutrophils recruited (20). The improved antimicrobial activity was also shown to 
be dependent on SP signaling and additional experiments will elucidate its 
effects on the production of NETs. NETosis has been shown to have 
antimicrobial activity against multiple organisms, which lends credence to 
broader applications to patients. NETosis activity can be stimulated by 
inflammatory cytokines, bacterial products, or DAMPs (13). Previous work in 
isolated neutrophils stimulated by IL-8 showed that SP treatment increased 
calcium flux in a dose dependent manner (47). Heightened responses to 
cytokines could be the mechanism of mTBI enhanced NET formation. Early 
studies using human whole blood with the NK1R agonist show a dose-dependent 
increase in bacterial killing. In addition, as demonstrated in mouse models, SP 
treatment by itself did not induce significant induction of pro-inflammatory 
cytokines. However, these data were obtained from a single donor and thus 
further studies are needed to make an accurate conclusion. Putting our results in 
the context of other findings, we propose that SP effects are elicited on a 
spectrum. On one end, increasing levels enhance innate immunity, as suggested 
by our human data. However, a tipping point is reached and deleterious effects 
come into play at high levels of SP, as demonstrated by Lorente in severe TBI 
patients (122). Our own measurements of SP show that within 30 min, mTBI 
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plasma levels are lower than the high mortality cutoff (>299pg/mL), with the large 
caveat it is in a different species. These results suggest that augmentation of 
innate immunity through SP may be beneficial for patients who are at risk or even 
those who are actively fighting infections.  
Although our focus is on innate immunity, widespread expression of the 
NK1R suggests that SP release would have far-reaching effects. Previous work 
shows effects on endothelial cells to assist adhesion and transmigration of 
PMNs. In endothelial monolayers, experiments showed that human umbilical 
venous endothelial cells (HUVECs) express increased ICAM-1, a molecule 
crucial to diapedesis (46). Other studies demonstrate that neutrophil migration 
across these experimental layers is enhanced (139). The importance of 
endothelial cells should not be understated, as increased cell recruitment without 
increases in neutrophil chemokine receptor might be explained through their 
actions. Macrophages can also be modulated in various ways by SP. SP 
treatment can alter macrophage phenotypes towards anti-inflammatory M2 
macrophages after spinal cord injury (96), but other evidence suggests that SP 
activates pro-inflammatory cytokine and chemokine production through multiple 
signaling pathways: PKC and PI3K-Akt (183), and ERK1/2 and p38 MAPK (184) 
pathways. This may be due to differences in NK1R isoform expression by 
macrophages (31). Crosstalk of macrophage NK1R signaling and cholinergic α7 
nAChR anti-inflammatory will also be of further interest due to the hypothesis that 
the inflammatory reflex, acting mainly on macrophages, is the second pathway 
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involved. Bone marrow macrophages can be stimulated to make granulocyte 
macrophage colony stimulating factor (GM-CSF) and IL-3 by SP stimulation 
(154). In chapter 2, we found no difference in circulating neutrophils or total 
WBCs at the time of pneumonia challenge. The initial trauma could stimulate 
granulopoiesis in the bone marrow to generate available reinforcements for a 
subsequent challenge. Our results show that PMNs isolated from the bone 
marrow are primed, thus SP’s effects must be penetrating into the marrow space 
in our model. Further work needs to be done to fully characterize the effects of 
SP.  
Clinical studies have implicated low serum SP levels in the development 
of dysphagia and subsequent aspiration pneumonia. As angiotensin converting 
enzyme (ACE) can break down substance P, it was shown that ACE inhibitor 
treated patients with cough had increased levels of sputum SP (188). An analysis 
of 13,382 patients who suffered from pneumonia following stroke showed that 
ACE inhibitor use was associated with a 30% decreased pneumonia risk in a 
dose-dependent relationship. (120). Another study used nicergoline, a treatment 
for dementia reported to increase serum SP level, in a prospective randomized 
clinical trial of elderly patients against an ACE inhibitor. Nakashima et al. found 
that both treatments significantly increased serum SP levels and reduced 
dysphagia. In addition, nicergoline treated patients had similar rates of 
pneumonia (9/30 ACE inhibitor, 5/30 nicergoline) (140). Although functional oral 
intake may be a large determinant of pneumonia risk in these patients, increased 
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SP could also contribute to reduced rates of infections. Accordingly, a review of 
clinical trials with aprepitant showed that three studies totaling 1480 patients 
reported tripling of the incidence of severe infection from 2% to 6% (51). These 
findings show that SP signaling through NK1R plays a critical role in primed 
neutrophil functions. In addition, clinical studies have shown reduced risk of 
pneumonia in patients treated with drugs that increase serum SP levels (120). 
Survival studies suggest that a second pathway is necessary to recapitulate the 
full effect of mTBI challenged with infections. Future studies should focus on the 
testing the generalization of the SP effect and whether it can be applied following 
infection. Translation of these findings shows that NK1R modulation could 
provide therapeutic benefit to fight infections.   
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Chapter 4: Vagal signaling through the α7 nicotinic acetylcholine receptor 
modulates pro-inflammatory cytokine production   
 
Introduction 
The vagus nerve is responsible for the inflammatory reflex, an anti-inflammatory 
circuit activated by noxious stimuli in the periphery. Efferent vagal signaling 
releases acetylcholine in the periphery that acts on α7 nicotinic acetylcholine 
receptor (α7 nAChR) on innate immune cells, primarily macrophages. 
Experiments in animal models show that vagal innervation of the spleen is 
required (91). The current proposed efferent circuit begins with vagal efferents 
synapsing onto the celiac ganglion, where the splenic nerve transduces the 
signal to macrophages in the spleen. However, the splenic nerve contains only 
noradrenergic signals, thus another intermediary is required. A subset of splenic 
T-cells produces and releases acetylcholine onto macrophages to complete this 
pathway (161). Ligand binding to the α7 nAChR initiates several pathways to 
downregulate the production of pro-inflammatory cytokines. The α7 nAChR can 
inhibit the phosphorylation of NF-κB (162, 214), form a heterodimer with JAK2-
STAT3 that upregulates suppressor of cytokine signaling 3 (SOCS3) (27, 44), or 
decrease MAPK phosphorylation by transient increases in intracellular Ca2+ 
(185). All of these pathways limit the production of pro-inflammatory cytokines by 
immune cells. This arm of inflammatory reflex is termed the cholinergic anti-
inflammatory pathway.  
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The cholinergic anti-inflammatory reflex is dependent on vagal signaling 
through the α7 nAChR. In 2003, this receptor was shown to be critical to 
modulating inflammation. Macrophages exhibit α7 nAChR on their surface, 
measured by the binding of fluorescent α-bungarotoxin, a specific α7 antagonist, 
to the membrane. Furthermore, only antisense nucleotides specific to α7 blocked 
the suppressive effect on inflammation in macrophages stimulated with LPS. α7-/- 
mice also exhibited increased cytokine production when challenged with LPS 
(202). Dependence on vagal signaling was shown in several animal models of 
disease by vagotomy. In a model of E.coli peritonitis, vagotomized animals 
exhibited increased neutrophil influx and production of pro-inflammatory 
cytokines. Nicotine, which binds to nAChR, was able to reverse this effect as a 
pretreatment and markedly reduced histological liver damage and liver function 
tests (198). However, nicotine treatment increased mortality. In a model of 
dextran sodium sulfate (DSS) induced colitis, vagotomized mice exhibited worse 
histologic scores, increased serum amyloid-P, colonic IL-1β/IL-6/TNFα. Nicotine 
treatment limited the damage and production of pro-inflammatory cytokines (65). 
Interestingly, anti-inflammatory reflex actions produce downregulation of pro-
inflammatory cytokines, but do not increase the production of anti-inflammatory 
cytokines, such as IL-10 (10, 44).  
As the inflammatory reflex is thought to negatively regulate the immune 
response, α7 receptors are expressed on the surface of various cells important to 
the immune response. Macrophage expression of α7 nAChR and their role in the 
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inflammatory reflex is well documented (44, 180, 202). Endothelial cells treated 
with α7 agonists have reduced activation reflected in decreased ICAM-1, VCAM-
1 and E-selectin expression. Endothelial cells can also produce chemokines in 
response to inflammatory stimuli. Nicotine treatment of endothelial cells blocked 
their TNFα-stimulated production of IL-8 along with leukocyte adhesion to and 
migration across endothelial cells (162). Both inhibition of NK-κB and activation 
of JAK2/STAT3 signaling were involved in endothelial activation of α7 nAChR. 
Neutrophils were confirmed to express α7 nAChR on their surface by 
immunofluorescence and flow cytometry. Stimulation of neutrophils with α7 
nAChR agonists attenuates production of MIP-2 after LPS stimulation. In 
addition, neutrophils from α7-/- mice expressed significantly higher levels of MIP-2 
and TNFα after LPS stimulation compared to wild-type control cells. This may 
indicate that α7 nAChR exerts a basal effect on neutrophil cytokine production 
(180). α7 nAChR activation on neutrophils was also shown to suppress F-actin 
polymerization, which in turn reduces CD11b and reduces PMN trafficking (92). 
These findings show that neuroimmune modulation through the inflammatory 
reflex can have significant changes on the immune response.  
TBI patients have sustained increases in vagal tone following injury (106). 
Measurement of heart-rate variability (HRV) is used as a surrogate for measuring 
sympathetic or parasympathetic activity, or vagal tone. High frequency HRV (HF) 
is associated with parasympathetic tone whereas low frequency HRV (LF) is a 
signal of sympathetic tone. TBI patients were shown to exhibit increased HF/LF 
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ratios, indicating parasympathetic dominance and vagal hyperactivity. This anti-
inflammatory dominance was proposed to be the source of susceptibility to 
infection by limiting the immune response to infections. Tracey proposed that the 
innate immune system sits at a certain set point to determine the strength of 
response to stimulation (189). Compromised vagal tone, such as in rheumatoid 
arthritis patients, increases magnitude of the inflammatory response and results 
in subsequent tissue damage. Activation of the inflammatory reflex is thought to 
acutely reduce the amplitude of this response and thus high tonic vagal activity 
could result in blunted immunity. Current clinical dogma proposes that this 
hyperactivity generates the immunosuppression seen in severe TBI patients.  
In contrast, our mTBI model has shown enhanced immune responses to 
pneumonia challenge with reduced production of pro-inflammatory cytokines. 
The previous chapter showed that NK1R agonism alone cannot enhance 
survival, thus we hypothesize that the cholinergic anti-inflammatory reflex may 
also be activated in our model to exert a brake on inflammation. These studies 
examine the role of this pathway and α7 nAChR signaling in the mTBI model. 
Using pharmacological manipulations of the α7 nAChR, we show that mTBI 
enhanced survival is dependent on signaling through this receptor.  
 
  
94 
Methods 
 
α7 nAChR pharmacological treatments 
Methyllycaconitine (MLA, 1mg/kg, saline), a specific α7 nAChR antagonist, was 
administered by i.p. injection 1h prior to TBI and every 12h up until pneumonia. A 
specific α7 agonist, GTS-21 (4mg/kg, saline), was administered i.p. to sham or 
tail trauma mice every 12h beginning with injury and ending prior or pneumonia. 
Sham injured mice were injected with vehicle.  
 
TBI and pneumonia models 
As previously described in Chapters 2 and 3. Note that some studies were done 
with sham injury mice prior to the approval and validation of the tail trauma 
model. TNFα in HBSS (R&D Systems, Minneapolis, MN) was administered to the 
Pseudomonas suspension for a final concentration of 1ng/50uL and then 50uL 
was instilled i.t. to the mice. Vehicle mice were administered Pseudomonas as 
previously described. Mortality for these experiments was followed for 14 days.  
 
Plasma/Tissue Samples 
Mice were sacrificed under ketamine/xylazine anesthesia followed by retroorbital 
exsanguination. Blood was collected into 100uL of heparin and spun at 1000g for 
5 min. Plasma was collected for cytokine analysis. BAL fluid was obtained as 
described previously. Briefly, 5mL of HBSS-EDTA (50:1) in 500uL aliquots was 
washed through the lungs. The first 1mL was used for cytokine measurements. 
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Bacterial burden was measured by serial dilutions of 100uL of the first 1mL onto 
blood agar plates.  
 
Cytokine and Lung Injury Measurements 
Cytokines were measured by sandwich ELISA using matched antibody pairs. 
Antibodies and standards were purchased from R&D systems. Albumin and IgM 
were measured by ELISA as previously described with minor modifications (143). 
Total protein in BAL fluid was measured by using a commercial assay kit 
(Coomassie Plus (Bradford) Assay Kit, Thermo Fisher Scientific). Bovine serum 
albumin (Sigma-Aldrich) was used to prepare the standard. Absorbance was 
read at 590nm.  
 
Physiologic Measurements and Whole Body Plethysmography 
Physiologic measurements were taken using cervical collar telemetry as 
described in previous chapters. Respiratory measurements were obtained using 
whole body plethysmography as described above (194). 
 
Western Blot for HMGB1 
BAL samples were collected at 24h following pneumonia as previously 
described. 2mL of sample was loaded into Centricon YM-10 filters (Amicon) and 
spun at 1500g for 2h. The retentate, the concentrated portion, was then 
recovered by an 800g spin for 2 min. For each sample,  equal starting volumes of 
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15uL was mixed with 5uL of 4X SDS-PAGE running buffer to denature at 80°C 
for 10 min. 15uL of each sample was loaded into a precast SDS-PAGE gel 
(NuPAGE Novex 4-12% Bis-Tris, 15 well 1.0mm). HMGB1 standards were 1:64, 
1:213, and 1:640 dilutions of 320ng/mL. The gel was run at 150 volts for 90 
minutes. Protein was transferred to a PVDF membrane for 2h at 300V/400mA. 
The membrane was removed and blocked for 60 min with Odyssey blocking 
buffer in PBS (LiCor) while gently shaking. 3 washes for 10 min each in tris-
buffered saline with triton (TBS-T) were performed. The membrane was 
incubated in primary antibody α-HMGB1 (Sigma, SAB2101049) in TBS-T+0.5% 
bovine serum albumin (BSA) overnight while shaking at 4°C. After three washes 
with TBS for 10 min each, secondary antibody IRDye® 680 (Goat α-Rabbit, 
1:10,000) was incubated for 1h in Odyssey blocking buffer (LiCor). Two washes 
in PBS followed. Membrane was scanned on an Odyssey near-infrared scanner 
(LiCor).  
 
Data Analysis 
Data was analyzed using Prism 6.0 (GraphPad). For experiments with more than 
two groups, one-way ANOVA with the appropriate post-tests between applicable 
groups was performed. Respiratory and physiologic parameters were analyzed 
by two-way ANOVA with post-tests between groups at each time point. 
Experiments between two groups were analyzed using a student’s t-test. Survival 
curves were analyzed by log-rank (Mantel-Cox) test. 
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Results 
α7 nAChR blockade eliminates the survival benefit of mTBI  
mTBI mice previously displayed reduced pro-inflammatory cytokine and 
chemokine levels in the BAL (209). We hypothesized that this effect was due to 
cholinergic anti-inflammatory pathway activation. To determine whether α7 
nAChRs play a role in the improved survival seen in our model, a specific α7 
nAChR antagonist, MLA was utilized. MLA treatment (1mg/kg) was initiated 1h 
prior to mTBI and repeated every 12h to block any sustained release of 
acetylcholine. 48h after trauma, mice were challenged with 0.5-1.0x108 CFU of 
Pseudomonas pneumonia. Antagonism of the α7 nAChR eliminated the survival 
benefit of mTBI, with similar mortality to sham mice (Fig 1). These data show that 
the inflammatory reflex plays a critical role in our mTBI model through signaling 
of the α7 nAChR.  
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α7 agonist treatment Improves survival without significant immunosuppression 
Previous work showed that α7 nAChR agonism using vagal nerve stimulation 
(VNS) or GTS-21, a specific α7 agonist, was able to improve outcomes in other 
models of infectious disease (148). Based on our MLA experiments, the 
cholinergic anti-inflammatory pathway is critical to improve survival. To determine 
whether α7 nAChR agonism could improve survival in our model, we tested GTS-
21 (4mg/kg, i.p.) in our pneumonia model. Agonist treatment significantly 
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Figure 4-1. Effect of a specific α7 nAChR antagonist, MLA.  
Blockade of the α7 nAChR eliminated the survival benefit of mTBI mice, but 
did not alter survival of sham injured mice. MLA was administered 1h prior to 
initiation of trauma and every 12h up to instillation of 0.5-1.0x108 CFU of 
Pseudomonas. Data analyzed by log-rank (Mantel-Cox) test. *p<0.05, 
***p<0.001 compared to mTBI (n=18 mTBI, n=18 sham, n=9 mTBI +α7 
antagonist, n-8 sham + α7 antagonist 
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improved pneumonia survival compared to sham/tail trauma mice (Figure 2a). As 
the inflammatory reflex can reduce cell recruitment and is hypothesized to cause 
immunosuppression following mTBI (68, 77), we measured BAL bacterial burden 
and cell recruitment to the airspaces. As before, mTBI mice have increased cell 
recruitment and bacterial clearance compared to either sham or sham+GTS-21 
treatment. GTS-21 treated mice did not display reduced alveolar PMNs or 
increased bacterial load compared to sham mice (Figure 2B&C). Interestingly, α7 
blockade in mTBI increased pulmonary neutrophil cell recruitment and decreased 
bacterial load. However, more mice need to be added to the MLA treatment 
group to confirm its effects on pulmonary immune responses. Although GTS-21 
treatment has not been previously been described to enhance survival in 
pneumonia, these experiments corroborate with other findings that α7 nAChR 
stimulation can improve outcomes in severe infection (148) 
  
  
100 
 
 
 
 
.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P s e u d o m o n a s  p n e u m o n ia  s u rv iv a l
0 2 4 6
0
2 0
4 0
6 0
8 0
1 0 0
S h am
m T B I
G T S -21
D a y s
P
e
rc
e
n
t 
s
u
rv
iv
a
l
****
A
B A L  N e u tro p h ils
S h a m S h a m
 +   7  a g o n is t
T B I T B I 
+   7  a n ta g o n is t
0
5
1 0
1 5
2 0
C
e
ll
s
/m
L
 (
1
0
^
6
)
*
*
****
B A L  C F U s
S h a m S h a m
 +   7  a g o n is t
T B I T B I 
+  a 7  a n ta g o n is t
0
1 0 0 0 0
2 0 0 0 0
3 0 0 0 0
4 0 0 0 0
5 0 0 0 0
C
F
U
/m
L
***
*
B C
 
Figure 4-2. Effect of α7 nAChR manipulations on survival and pulmonary immune 
response to pneumonia. 
 Mice were administered either a specific α7 nAChR agonist, GTS-21 (4mg/kg i.p.) 
every 12h or antagonist, MLA (1mg/kg, i.p.) 1h prior to trauma and then every 12h 
after. Pneumonia was instilled 48h following injury (A) α7 agonism in sham mice is 
able to replicate the survival benefit of mTBI. Data analyzed by log-rank test. 
****p<0.0001 compared to mTBI (B,C) At 4h post-pneumonia, mTBI mice have 
increased pulmonary neutrophils and reduced bacterial burden. GTS-21 treatment 
does not significantly reduce the influx of cells or increase bacterial load. TBI+MLA 
treatment significantly increases both neutrophil recruitment compared to all other 
groups. Data analyzed by one-way ANOVA with Sidak’s post test. *p<0.05, 
***p<0.001, ****p<0.0001  
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α7 does not alter early respiratory or physiologic parameters   
To determine the mechanism by which α7 nAChR agonism enhances survival, 
we sought to investigate various physiological parameters. To pinpoint specific 
mechanisms by which the anti-inflammatory pathway may be enhancing survival, 
we investigated physiologic and respiratory parameters. Our Pseudomonas 
pneumonia is a model of severe infection, thus changes to these parameters 
may help to guide further experiments into the mechanism of how the 
inflammatory reflex improves survival. MouseOx physiologic measurements 
inform of us systemic dysfunction while whole body plethysmography has been 
previously reported to be a sensitive measure of pulmonary inflammation and 
lung damage (194). Physiologic and respiratory parameters were taken at 48h, 
immediately prior to pneumonia, then 6 and 24h following the bacterial challenge. 
GTS-21 mice exhibited significantly higher heart rates compared to mTBI mice 
prior to and at 24h after pneumonia. mTBI mice have reduced respiratory rates 
by MouseOx at 24h following pneumonia compared to sham mice, but WBP, 
which is more specific, indicated no significant differences. There were no 
differences between groups in respiratory parameters measured, but the 
infection did have a significant effect on lung parameters. These tools may not be 
detailed enough to provide discriminatory data on the health of the mice between 
groups. Previous literature shows that inflammatory reflex activation results in 
significant alterations to molecular pathways to result in improved outcomes.  
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Figure 4-3. Physiologic and respiratory parameters during pneumonia. 
(A) Physiologic parameters measured by MouseOx. mTBI mice have lower 
respiratory rate at 24h post-PNA. Pre-PNA and at 24h post-PNA, GTS-21 mice have 
higher heart rates. (B) Whole body plethysmography demonstrated no difference in 
pulmonary function between groups at time points. Data shown as mean±SEM. Data 
analyzed by two-way ANOVA with Tukey’s post-test between groups at each time 
point. *p<0.05 mTBI vs GTS-21, @ p<0.05 Sham vs mTBI 
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GTS-21 reduces pro-inflammatory cytokine production 
In other models of inflammatory disease, α7 nAChR signaling reduces pro-
inflammatory cytokine production. Earlier work in our mTBI model also displayed 
reduced pro-inflammatory cytokines in both BAL fluid and plasma compared to 
sham injured mice (209). We sought to test whether GTS-21 was able to 
recapitulate these effects. We measured plasma IL-6, IL-10, MIP-2, BAL IL-6, 
MIP-2, and TNFα by sandwich ELISA. In plasma, IL-6 and MIP-2 were 
significantly decreased in mTBI and GTS-21 treated mice compared to sham 
injured mice (Fig. 4). GTS-21 reproduced the decreased levels of TNFα in BAL 
fluid seen in mTBI mice. Previous literature in an E.coli model of severe 
pneumonia showed reduced pro-inflammatory cytokines and lung injury with 
nicotine treatment (180). Interestingly, BAL MIP-2 is increased by GTS-21 
treatment in sham mice. We expected overall downregulation of pro-inflammatory 
mediators, but in the context of reduced plasma MIP-2 levels, it may point to shift 
from the aberrant chemotactic gradient in sham mice. These data suggest that 
modulation of local pro-inflammatory cytokines could be the mechanism by which 
cholinergic signaling contributes to improved survival.   
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Figure 4-4. Cytokine responses at 4h following pneumonia.  
(A) mTBI and GTS-21 treatment significantly reduce plasma IL-6 levels compared to 
sham. (B) No significant differences between groups. (C) Plasma MIP-2 levels are 
significantly different between all groups. (D) Sham MIP-2 levels are significantly 
lower in BAL fluid compared to GTS-21 treatment. (E) No significant differences in 
plasma IL-10 levels. (F) GTS-21 and mTBI have significantly decreased TNFα levels 
compared to sham mice. Data shown as mean±SEM and analyzed by one-way 
ANOVA with Tukey’s post-test.  
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TNFα is not responsible for increased lung injury following pneumonia 
Pro-inflammatory cytokine production can induce local tissue damage that results 
in worse outcomes. Cytokine measurements suggest that increased local TNFα 
may be the cause of increased mortality in sham mice. At 4h, the difference was 
approximately 1ng/mL in groups that exhibit enhanced survival compared to 
sham injury mice. To investigate whether locally elevated TNFα concentrations is 
responsible for increased tissue damage, recombinant TNFα or saline was added 
to Pseudomonas pneumonia for instillation into either mTBI or GTS-21 treated 
mice. Mortality was followed for each of these groups (TBI, TBI+TNFα, GTS-21, 
GTS-21+TNFα) for 14 days, in case TNFα treatment induced later mortality. No 
significant differences in mortality were found between either TBI or GTS-21 and 
their cytokine replaced counterpart (Figure 5a).  
Although TNFα did not increase mortality in these groups, we sought to 
measure lung injury as a more sensitive measure of tissue damage. Using the 
American Thoracic Society (ATS) guidelines for measuring lung injury, we 
measured total BAL protein concentration, a lower, and a high molecular weight 
protein concentration (130). Measurement of these parameters shows alveolar-
capillary barrier integrity. Increasing compromise of the barrier allows larger 
molecules to pass, such as IgM compared to albumin. Thus, measuring several 
different molecules allows us to identify the extent of injury. Mice were sacrificed 
for BAL fluid 24h following instillation of pneumonia or pneumonia+TNFα. Total 
protein was measured by Bradford assay while IgM and albumin were measured 
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by ELISA. Early addition of TNFα did not significantly increase lung injury 
parameters following pneumonia in either of the groups (Fig 5 B-D). These data 
suggest that prevention of early local pro-inflammatory cytokine production 
through mTBI or α7 nAChR activation does not contribute to enhanced survival 
through magnified lung injury.  
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Figure 4-5. Replacement of TNFα early with Pseudomonas pneumonia 
Replacement of TNFα early in infection did not have an effect on lung injury. 
1mg of TNFα was administered in conjunction with pneumonia challenge. (A) 
Mortality was followed for 14 days after infection. No significant differences 
between groups and respective TNFα were found. (B,C,D) 24h after 
pneumonia, BAL was performed to measure indicators of lung damage. Data 
shown as mean±SEM and analyzed by one-way ANOVA with Sidak’s post-
test.  
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mTBI downregulates HMGB1 release in BAL   
High mobility group box 1 (HMGB1) is a DAMP that has been shown to mediate 
late end-organ damage (123). Normally, HMGB1 interacts with DNA to facilitate 
protein binding, but it can be secreted as a signal or released due to cellular 
damage. This molecule has different signaling products based on is redox state, 
but induces pro-inflammatory cytokine damage through NF-κB activation. Studies 
that manipulate the inflammatory reflex provide evidence that α7 nAChR agonism 
alters production of this damaging molecule (90, 201). HMGB1 levels were 
assessed by western blot in the BAL fluid of mice 24h following injury after 
concentration with Centricon filters. mTBI mice exhibited little to no HMGB1 
signal whereas sham mice had evident bands for HMGB1 (Fig 6). This blot 
indicates that decreased expression of HMGB1 may be the critical step in 
reducing mortality in our model. These bands were loaded with equal volumes of 
concentrated BAL fluid as our normalization step to ensure that excess protein 
leakage into the BAL would not reduce the detectable level of HMGB1. Future 
work should assess the extracellular content with normalized protein content. In 
addition, the BAL fluid is acellular, thus the blot represents HMGB1 secreted from 
cells or released from necrotic ones, not protein expressed inside cells. Based on 
these findings, we propose that mTBI or α7 agonism enhances survival by 
decreased release of HMGB1.  Further work will be necessary to fully elucidate 
the mechanism of HMGB1 in our model. 
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Figure 4-6. HMGB1 Western Blot.  
Near-infrared scan of α-HMGB1 western blot of BAL fluid obtained 24h after 
pneumonia. S = sham, T = mTBI. Each lane represents one mouse. Sham 
mice show detectable levels of HMGB1 while mTBI mice do not. Arrows 
indicate HMGB1 band 
  
110 
Discussion 
These studies show that the inflammatory reflex through α7 nAChR is critical to 
mediating enhanced survival following a bacterial pneumonia challenge. 
Interestingly, agonism of only the anti-inflammatory pathway was able to improve 
survival to similar levels of mTBI mice with treatment prior to or after instillation of 
pneumonia. This improvement in mortality is reflected in reduced early local 
cytokine production at 4h without changes to physiologic or respiratory 
parameters. Western blot analysis shows that HMGB1 in BAL fluid is markedly 
reduced in mTBI mice. These data support a mechanism where mTBI activates 
the vagal anti-inflammatory reflex to reduce local pro-inflammatory cytokine 
production and late mediators of end-organ damage. Future work will explore the 
connection between reducing early pro-inflammatory cytokine production and late 
end-organ mediators using neuroimmune modulation. 
These data from our model of mild TBI contrasts the current clinical 
paradigm that excess vagal tone induces immosuppression. Although the α7 
agonism in our model may not be reflective of high tonic vagal tone, mimicking 
the inflammatory reflex activation did not increase bacterial burden or 
demonstrate blunted immune response. As with most other physiologic systems, 
vagal activity most likely sits on a spectrum. Moderate activation benefits the 
organism by limiting the intensity of a second inflammatory insult, as we have 
shown above. Intense, sustained activation of the cholinergic anti-inflammatory 
system blunts the immune response to cause immunosuppression. This 
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mechanism is supported by evidence that α7 nAChR signaling can decrease 
neutrophil recruitment to the site in animal models, while knockout mice increase 
recruitment. Giebelen et al showed that α7-/- KO mice challenged by an 
intraperitoneal infection in E.coli cleared bacterial better. Compared to wild-type 
mice, KO mice accelerated neutrophil recruitment, increased bacterial clearance, 
and limited dissemination (67). Accordingly, cholinergic stimulation was shown to 
reduce neutrophil recruitment. Saeed et al. demonstrated that endothelial cells 
treated with nicotine had limited activation when stimulated by TNFα. In addition, 
mice treated with vagal nerve stimulation (VNS) or nicotine decreased neutrophil 
recruitment to a carrageenan air pouch model of inflammation (162). Further 
work will be required to identify situations where cholinergic signaling may be 
beneficial. On one side, decreased pro-inflammatory cytokine production may 
also lead to decreases in the early clearance of pathogens, which has been 
shown to be a key determinant in outcomes in severe infections (40). On the 
other, work has been shown that cholinergic signaling ameliorates tissue 
damage, despite reduced PMN influx and pro-inflammatory cytokine production 
(180). 
Significant evidence exists in animal models of disease that the 
cholinergic anti-inflammatory pathway is beneficial in improving disease activity 
or survival. Models of arthritis, sepsis, acute lung injury, colitis, pancreatitis, and 
ventilator induced lung injury have all shown improved outcomes after 
modulation with α7 nAChR, with a common theme of decreased pro-
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inflammatory mediators (189).  In two separate rodent studies of collagen-
induced arthritis, a model of rheumatoid arthritis, both vagal nerve stimulation 
(VNS) and α7 agonist treatments ameliorated inflammation (116, 196). Similarly, 
pancreatitis induced by cerulein injection in mice was exacerbated by vagotomy 
or blockade of α7 nAChR signaling. In addition, they showed diminished severity 
of pancreatitis following GTS-21 pretreatment (197). However, a few experiments 
in peritonitis models have shown that α7 nAChR signaling can play a detrimental 
role. One study showed that while nicotine pretreatment decreased histological 
damage and liver function tests, mortality was actually significantly accelerated 
(198). A later study showed that α7-/- mice cleared E.coli peritonitis quicker than 
wild-type mice (67). While many of these studies used pretreatment, patients 
generally present with the inflammatory process in full force. Future studies 
should focus on α7 nAChR agonism during the course of inflammatory diseases, 
however, this may be detrimental in severe infections where microbial control is 
paramount. Thus, balancing neuroimmune activation to reduce inflammatory 
damage without interfering with cellular responses will be crucial to translating 
these findings from the bench. 
In patients, high frequency HRV indicates increased parasympathetic 
activity through vagal tone. In patients with sepsis, reduced HRV (both low and 
high frequency) correlated with patients who developed organ failure during the 
hospital stay (151). In studies of rheumatoid arthritis patients, they exhibited 
decreased high frequency HRV compared to healthy controls and this was 
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accompanied by increased serum levels of HMGB1 and C-reactive protein (CRP) 
(58, 70). These data also support that preexisting vagal activity affects the 
immune response. The reduced ability to curtail pro-inflammatory stimuli drives 
further damage in these diseases. Current clinical trials focus on the use of α7 
nAChR agonists to treat neurocognitive disorders. However, selective VNS is 
being tested for its efficacy in inflammatory disorders like Crohn’s disease and 
rheumatoid arthritis.  
One study using pretreatment of GTS-21 on endotoxemia responses 
showed a correlation between the active metabolite 4-OH GTS-21 plasma 
concentration and decreased pro-inflammatory cytokines. Although there was no 
significant difference between placebo and treatment cytokine levels, this may 
also be due to the high variability in treatment plasma concentrations as noted by 
the authors. However, higher 4-OH GTS-21 metabolite plasma concentrations 
were significantly correlated with lower TNFα levels (105). These same authors 
recently showed that transcutaneous VNS has no effect on pro-inflammatory 
cytokine production induced by endotoxin challenge (107). Despite these early 
failures, endotoxin administration does not fully recapitulate the course and 
severity of bacterial infections in humans. Promising findings are not always 
applicable to the bedside, but further characterization of inflammatory reflex 
contribution is needed to fully understand its application.  
These experiments show that the cholinergic anti-inflammatory pathway 
through α7 nAChR signaling plays a critical role in mTBI increasing survival. 
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Further work into the importance of reducing local pro-inflammatory mediators is 
warranted to fully understand the mechanism in our model. Current clinical 
studies mainly focus on neurocognitive disorders, with some trials on 
inflammatory diseases. This study offers evidence that translation of α7 nAChR 
agonism into patients has potential to improve outcomes in patients with 
pneumonia.  
.
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Chapter 5: Discussion  
 
TBIs and Immunosuppression 
Our findings run contrary to the prevailing dogma that TBIs cause 
immunosuppression. Multiple clinical studies reported that patients with TBIs 
have high rates of infection, especially pneumonia, during the course of 
hospitalization. An early retrospective study of eighty-two head trauma patients 
showed that 41 (50%) developed an infectious complication and 34 of those were 
early respiratory infections (84). Berrouane et al reported that neurotrauma 
patients had increased risk of pneumonia compared to non-trauma controls in a 
neurosurgical intensive care unit. The incidence was 20.1 cases of pneumonia 
per 1000 patient days for trauma compared to 15.7 per 1000 patient days for 
nontrauma patients. A single-center prospective study by Zygun showed that 
45% of severe head trauma patients developed ventilator associated pneumonia 
(219). These numbers were corroborated with a large retrospective study of 760 
TBI patients, of which 214 (28.1%) developed an infection (104). Several 
different pathways have been hypothesized to generate this immunosuppressive 
state, such as excess cholinergic signaling, dysregulated HPA axis, or 
sympathetic storm (82).  
However, previous work from our lab counters this paradigm. Using the 
National Trauma Data Bank (NTDB), increasing TBI severity was associated with 
higher risk of pneumonia. The need for mechanical ventilation was 2.5 times 
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higher in TBI patients and recent work shows that every day on ventilation 
increases pneumonia risk by ~7% (89). Propensity score matching (PSM) 
allowed us to limit confounding variables to estimate the effect of a single 
intervention (ex. TBI) between groups with and without brain injury. PSM was 
used to match cohorts requiring mechanical ventilation of mild, moderate, and 
severe TBI to blunt trauma patients, most notably equalizing injury severity score 
between comparisons. After PSM, TBI patients showed ~25% reduced incidence 
of pneumonia compared to their blunt trauma counterparts. Interestingly, this 
effect was apparent in nonventilated mTBI patients compared blunt trauma 
controls (209). This analysis of a large data set showed that TBI patients have a 
reduced rate of pneumonia compared to matched blunt trauma controls. These 
results underscore the importance of proper controls for comparison between 
groups.  
 
Animal Models of Trauma 
A valid criticism of our initial comparison between sham injury and mTBI 
was whether any trauma could initiate similar priming. Thus, development of the 
tail trauma model was necessary to provide a proper control. Multiple other 
trauma models have been characterized that show prior injury alters immunity. 
Thus, it was important to provide an appropriate non-head trauma injury that 
replicated several features from our mTBI model. As our mTBI model does not 
induce skull fractures, we wanted to avoid peripheral trauma that induces bone 
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breaks. A closed femur fracture model showed marked immunosuppression 
documented by reduced splenocyte blastogenesis following injury (141). Recent 
work from the Hauser group showed that damage associated molecular patterns 
(DAMPs) from pseudofracture models cause pulmonary immunosuppression. 
Pseudofracture was achieved in rats by injection of human bone supernatant into 
the thigh muscle. Rats with pseudofracture challenged with Staphylococcus 
aureus demonstrated reduced bacterial clearance. Formylated peptides in bone 
supernatants were responsible for suppressing chemotaxis and neutrophil 
extracellular trap (NET) formation (118). These models would not be appropriate 
comparisons for our mTBI model.  
 Skin alterations can also impact immunity. Our mTBI is a closed head 
injury, unlike several models of controlled cortical impact that rely on craniotomy 
to directly injure the brain (164). Different reports show that skin trauma or 
breaching of the peritoneum, such as in a hepatic crush model, may impact 
immunity. Rats undergoing laparotomy or midline incisions had reductions in their 
delayed-type hypersensitivity response (119). A separate report showed that 
sterile wounding of human skin induced increased expression of antimicrobial 
proteins. In vivo incisions on mice also showed similar induction of antimicrobial 
protein expression around the wound site (175). Several models avoid incisions, 
but either target the lungs, such as a pulmonary contusion model, or potentially 
cause diaphragmatic compromise due to the proximity of injury in a weight drop 
hepatic crush (142). In the pulmonary contusion (PC) model, early neutrophil 
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recruitment to the lung causes pulmonary dysfunction. PC mice treated with α-
Ly6G antibody to deplete neutrophils reduced lung injury (87). Using this model 
would pose concerns about initial differences in pulmonary function and 
neutrophils already recruited to the site prior to infectious challenge. In a follow 
up report, these mice were subjected to cecal-ligation and puncture (CLP) of 
sepsis 24h following PC. PC + CLP mice had significantly more mortality due to 
reductions in Sirtuin1 (SIRT1) expression and activity (174). Therefore, pre-
existing injury or reduced lung function present confounding variables as we are 
studying a pulmonary infection. Thus, mild tail trauma was chosen as our model 
to mimic mTBI injury severity while avoiding the aforementioned concerns.  
 
Trauma and Immune Priming 
Trauma induced alterations of the immune system are not novel 
phenomena, often described as a two-hit response where the initial trauma 
exaggerates the second stimulus to cause severe damage. Traumatic 
divergence from immune homeostasis has been divided into either generation of 
systemic inflammatory response syndrome (SIRS) or compensatory anti-
inflammatory response syndrome (CARS). SIRS and CARS are modeled to sit 
on opposite ends of the spectrum when challenged with a second hit. SIRS 
heightened immune responses cause excess damage whereas CARS dampens 
responses which may allow the infection to run rampant inside the host (179). 
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Two reports from the Lederer group describe a burn model that improved 
survival in E.coli peritonitis but reduced survival with LPS. Burn + LPS mice 
showed significantly more lung and liver damage and increased pro-inflammatory 
cytokines in those organs. However, anti-TNFα antibodies reversed this effect 
and enhanced survival (138). Burned mice with infectious peritonitis had 
increased circulating and peritoneal neutrophils and monocytes/macrophages at 
7 days post-injury. Neutrophils from burned mice had higher NADPH oxidase 
activity and E.coli killing. Importantly, this model also had significantly increased 
pro-inflammatory cytokines TNFα, IL-6, and MCP-1 (131). The authors 
suggested that the dosage of E.coli contained 100-fold less endotoxin than direct 
LPS challenge. This difference could drive increased inflammation that cannot be 
normally contained, similar to a light compared to a heavy second hit. The 
improved survival of burn+LPS mice after α-TNFα treatment supports this. An 
important difference between their priming and ours is that they demonstrate an 
increased level of circulating leukocytes. The immune priming supports our 
model, but a key distinction is that mTBI mice reduce both bacterial burden and 
pro-inflammatory cytokines. 
Whether their burn model priming is from trauma or through neuroimmune 
signaling is not known. Studies using skin from partial-thickness burn patients 
showed that SP+ nerve fibers were absent in early wounds, but maximally 
regenerated by 2 weeks following injury. The authors suggest that burn injury 
causes release of SP to drive enhanced inflammation (55). Interestingly, this 
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repopulation of SP+ immunoreactive fibers coincides with the timing of enhanced 
clearance of E.coli from the Lederer group. SP release in a murine burn model 
has been shown to cause lung injury. Following a 30% total body surface area, 
SP expression was increased that drove elevated levels of IL-1β, TNFα, IL6. In 
this study using NK1R antagonism and in a follow up study using SP gene 
(PPTA-/-) knockouts, pulmonary damage following burn injury was ameliorated. 
These results suggest that if the extent of neuroimmune priming is due solely to 
SP, similar to our NK1R agonist studies, then immune activation is enhanced that 
results in exaggerated responses and further damage. Neuroimmune signaling in 
our model appears to provide a novel priming that solves this dilemma by 
simultaneously activating enhanced neutrophil function while dampening pro-
inflammatory mediators. The interplay between cholinergic and neuroimmune 
signaling should be further investigated, as recent research demonstrates 
overlap between our proposed mechanism.  
 
Substance P and Wound Healing  
 While our current findings show that SP has immunity boosting effects, 
others have shown its potential for wound healing. Diabetic patients are at 
increased risk for ulceration and poor wound healing due to a combination of 
peripheral neuropathy and microvascular pathology (60). A recent study by Dang 
et al. showed that Type II diabetic patients had reduced SP+ innervation of the 
bone marrow with reduced serum levels of SP. These patients were shown to 
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have reduced mobilization of CD34+NK1R+ hematopoietic stem cells (HSPCs). 
Using Leprdb/db mice, a model for diabetes, they showed similar reduction in SP+ 
innveration of the bone marrow. These mice reproduced the impaired release of 
HPSCs following unilateral limb ischemia. G-CSF stimulation of the bone marrow 
to release HSPCs was tested in diabetic patients versus healthy controls for 
mobilization of cells and changes in serum SP levels. Diabetic patients also had 
reduced mobilization of CD34+ cells as well as decreased SP levels evoked by 
stimulation. Interestingly, patients with no change or a decrease in serum SP 
level had significantly lower mobilization compared to diabetic patients who 
elevated SP levels after G-CSF treatment (42). Another study by Leal et al. used 
mice with deletions for either the Tac1 gene encoding SP or NK1R-/- mice to 
show that SP signaling was important for diabetic wound healing.  Mice with 
diabetes induced by streptozotocin (STZ) had reduced skin SP gene expression 
and increased expression of neutral endopeptidase, which breaks down SP.  In 
diabetic mice, they found an increased ratio of pro-inflammatory M1:M2 
macrophage phenotype with concomitant increases in MCP-1. Interestingly, 10d 
after wound induction, topical SP treatment reverses this ratio that may indicate 
its importance in ameliorating the early inflammatory state. Diabetic mice had 
increased levels of matrix metalloproteinase-9 (MMP-9) compared to nondiabetic 
mice and SP treatment decreased MMP-9 expression in diabetic mice at 3d and 
10d after wounding (112). These results suggest that SP is critical to wound 
healing. Recent research by Park et al. in STZ-induced diabetic mice showed 
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that treatment with 5nM/kg SP i.v. accelerates wound healing. Two weeks after 
injury, SP treated wounds had improved vascularization and angiogenesis of the 
wound with reduced leukocyte infiltration. Importantly, SP treatment increased 
the proportion of mesenchymal stem cells (MSCs) identified by CD45-
CD29+CD105+ in both bone marrow and the peripheral blood (147). Dubon and 
Park also showed that SP can improve the properties of murine MSC-like cell 
lines, ST2 and OP9. ST2 cells treated with SP had increased mobilization in a 
wound scratch assay, but no increase in proliferation. OP9 cells tracked by BrdU 
showed increased proliferation following SP treatment (54). The combination of 
these results suggests that SP plays a critical role in wound healing through 
mobilization of MSCs and promoting M2 macrophages. mTBI induced SP 
production and subsequent signaling could be inducing mobilization of MSCs into 
circulation or increase their homing to the site of infection. In a rabbit model 
corneal burn model, SP mobilized CD29+ MSCs from the bone marrow that 
accelerated wound healing. Cultured human MSCs showed increased migration 
and proliferation due to activation of Erk1/2 and β-catenin pathways in response 
to SP (86). 
Work in pneumonia models shows that addition of MSCs to the lung can 
improve survival. Two studies of E.coli pneumonia demonstrated improved 
survival with MSC treatment. Gupta et al. showed intratracheal administration of 
MSCs improved survival through reduced bacterial burden and lung injury. This 
effect was reliant on MSC driving enhanced production of lipocalin 2 by alveolar 
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macrophages in a co-culture study. Lipocalin 2 is an antimicrobial protein that is 
thought to work by sequestering iron to limit bacteria replication (73). Monsel et 
al. used human bone marrow derived MSCs to show that CD44 uptake of MSC-
derived microvesicles (MSC-MV) improved survival in a keratinocyte-derived 
growth factor dependent manner. Interestingly, MSC-MVs reduced total WBC, 
neutrophils, protein, and pro-inflammatory cytokines in the BAL fluid while 
increasing bacterial clearance. MSC-MV treatment in cultured monocytes also 
improved their phagocytosis ability. In a Klebsiella pneumoniae model, flow-
sorted MSCs were given i.t. 4h following infection. MSC treatment reduced lung 
injury by protein measurements and dendritic cell infiltration. Notably, treatment 
after the infection did not change bacterial loads at 2d or 5d, but did improve 
pneumonia survival (74). These reports suggest that further exploration into 
neurokinin signaling on wound healing through MSC cells in our model may lead 
to valuable insights.  
 
Vagal Nerve Stimulation: Human Studies 
Human studies have shown that activity of the vagal nerve can exert tonic 
effects on the immune system. A clinical study compared HRV in rheumatoid 
arthritis (RA) patients against healthy controls. RA patients were shown to have 
lower basal vagal activity, which would fuel the inflammation that attacks the 
joints (58). Similarly, a cohort of septic patients who presented with reduced HF-
HRV indicative of decreased parasympathetic activity, showed increased rates of 
  
124 
multiorgan dysfunction syndrome (MODS) (151). Interestingly, Kox et al. trained 
volunteers to voluntarily activate their sympathetic nervous system. This cohort 
and untrained subjects were challenged with endotoxin. The trained group had 
increased IL-10 expression and decreased TNF-α, IL-6, and IL-8 compared to 
untrained controls. This suggests that activation of the sympathetic nervous 
system can control innate immunity by suppressing immune responses (108). 
These findings are somewhat discordant with the above patient studies, whose 
immune systems are released from vagal tonic inhibition whereas trained 
volunteers are inducing IL-10 mediated dampening. Previous studies have 
shown that cholinergic anti-inflammatory pathway activation does not modulate 
IL-10 (10). Thus, the intersection of these systems requires further research as 
activation of either parasympathetic or sympathetic have the potential for 
immunosuppression. 
Vagal nerve stimulation (VNS) in humans has been investigated as a 
treatment for epilepsy with surgical implantation of the device along the left vagus 
nerve (6). Studies are now being initiated in inflammatory diseases in humans, 
due to the promising results from basic research. Several studies are currently 
underway to measure physiologic variables as well as ex vivo response to 
inflammatory stimuli after VNS. Despite the enthusiasm from models of collagen-
induced arthritis, a clinical trial studying VNS application in rheumatoid arthritis 
patients was terminated due to lack of significant improvements (116),. Currently, 
another study is recruiting for Crohn’s disease, an inflammatory bowel disease 
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(9). An early report from a pilot study of seven patients followed up after 6 
months of VNS demonstrated that five had signs of clinical remission while two 
were removed due to worsening symptoms. These are promising results for 
clinical translation, as implantation of the stimulator was well tolerated in all 
patients.   
 
Vagal Nerve Signaling: Animal Studies 
Specific α7 agonism has demonstrated beneficial effects in several animal 
models. In a localized acute kidney injury model using LPS to induce renal 
damage, GTS-21 reduced the extent of injury. α7 agonist treatment decreased 
NF-κB activation to reduce kidney injury as well as neutrophil infiltration (28). 
Using macrophage cell cultures, Pavlov et al. demonstrated that GTS-21 
treatment inhibits release of TNFα and HMGB1 after LPS challenge. In a CLP 
model, GTS improved survival and decreased serum HMGB1 levels (148). 
Pancreatitis severity is mice can also be mitigated by α7 nAChR modulation. van 
Westerloo et al. used cerulein to induce pancreatitis in mice treated with 
vagotomy, GTS-21, or mecamylamine, a nicotinic receptor antagonist. Both the 
antagonist and vagomomized mice increased pancreatic injury, edema, and 
neutrophil infiltration. GTS-21 pretreatment reduced the severity of pancreatitis 
(197). In contrast, Lafarque et al. found that α7 nAChR activation resulted in 
worse outcomes. Using a middle cerebral artery occlusion model followed by 
Pseudomonas pneumonia, lung injury and mortality was reduced in α7-/- or MLA 
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treated mice. Activation of α7 nAChR using PNU-282987 in their model 
increased lung injury from Pseudomonas. PNU-282987, an α7 agonist, treatment 
also decreased bacterial killing in murine alveolar macrophage cultures and 
primary neutrophils (111). Stroke induced activation may induce stronger vagal 
cholinergic signaling to acutely blunt the immune response whereas augmenting 
weak inflammatory reflex activity in sepsis models is beneficial. Measurements of 
vagal tone using HRV may be necessary for deciding course of cholinergic 
treatments. Although these murine models do not fully recapitulate clinical 
scenarios, the number of positive results provides a promising basis of future 
drug discovery for α7 nAChR modulators. GTS-21 has been tested in human 
patients but had problems with highly variable plasma concentrations. Reduced 
levels of TNFα, IL-6 and IL-1RA were inversely correlated with GTS-21 
metabolite concentrations, but treatment was not significantly different, potentially 
owing to high variability between patients (105). Preliminary results from VNS in 
Crohn’s disease showed that vagal tone shifts toward normal levels with 
prolonged treatment (9). Different initial vagal activity combined with variable 
bioavailability may account for the spread of responses in human GTS-21 
studies. Further research is necessary to delve into the efficacy of manipulating 
cholinergic signaling in patients. 
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Antibiotic Resistance 
The underlying importance of these findings is the translation to fighting 
infections in patients. Antibiotic resistance is becoming ubiquitous. Solving this 
problem requires new innovations to circumvent microbial adaptations. Studies 
showed that multidrug resistant (MDR) Pseudomonas expresses reduced 
virulence factors compared to sensitive controls (45) and methicillin-resistant 
Staphyloccocus aureus (MRSA) was comparable to methicillin-sensitive 
Staphylococcus aureus (MSSA) in vulnerability to innate immunity (134). A 
recent report from Japanese hospitals shows that MDR Pseudomonas species 
produce less pyocanin, a toxin responsible for much of Pseudomonas’ virulence. 
Interestingly, transfection of the metallo-β-lactamase resistance gene caused 
reduced production of pyocanin in Pseudomonas (64). A prospective clinical 
study of 815 patients with nosocomial bacteremia due to Staphylococcus aureus 
showed a two-fold increase in deaths attributable MRSA compared to MSSA, but 
no difference in the rate of disseminated infections. This may be evidence that 
improving innate immunity circumvents the problem of diminished antibiotic 
efficacy in patients. The CDC houses a repository of established and emerging 
antibiotic resistant threats to be studied (25). Our studies identify NK1R and α7 
nAChR as targets for neuroimmunomodulation. Expanding tests into different 
organisms, especially antibiotic resistant strains from the CDC, could show 
benefit in broader application. Our collaborators tested mTBI in the cecal ligation 
and puncture (CLP) model of sepsis and showed improved outcomes 
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(unpublished work). This neuroimmune activation could prove valuable in fighting 
or preventing a variety of antibiotic resistant infections. In addition, curbing the 
use of antibiotics could limit the serious side effects of antibiotic treatment, such 
as the development of C. difficile infections (103). This work establishes a basis 
from which further exploration into these therapeutic targets should be pursued to 
improve treatments for infections.  
 
Interplay of Signaling  
Our experiments show that both pathways play a role in the enhanced 
immune response following mTBI. On one hand, neurokinin signaling enhances 
the microbial clearance. On the other, cholinergic signaling reduces tissue 
damage by reducing pro-inflammatory mediators. A murine model of influenza 
followed by bioluminescent Streptococcus pneumoniae secondary pneumonia 
demonstrated this hypothesis using drug therapy. In these mice, ampicillin with or 
without dexamethasone was administered when secondary pneumonia was 
detected by bioluminescence. Dexamethasone administration with ampicillin 
increased survival of mice with both severe and mild pneumonia by decreasing 
lung inflammation and permeability. However, treatment too early regardless of 
pneumonia status, blocked this benefit through immunosuppression (66). 
Ghoneim proposed that rapid antibiotic lysis of bacterial cell walls produces high 
concentrations of PAMPs that drives excessive inflammation. Combinatorial 
effects of corticosteroid blunting this response and ampicillin aided clearance of 
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bacteria produces improved survival. A large multicenter randomized clinical trial 
tested prednisone versus placebo for community acquired pneumonia. The 
primary endpoint studied was time to clinical stability for hospitalized patients. 
Corticosteroid treated patients had reduced time to clinical stability without 
increases in pneumonia-associated complications (8). These data show that in 
both patients and mice, increases in bacterial elimination coupled with anti-
inflammatory agents can improve outcomes. These findings help to reconcile 
dual activation of pathways that enhance immune function while reducing pro-
inflammatory mediators. Neurokinin and cholinergic signaling respectively 
replicate these actions and thus may prove beneficial in patients.  
 
Substance P Priming 
mTBI signaling shows that neutrophils in the bone marrow were primed, 
showing the far reaching effect of SP. Neurokinin signaling could play a 
significant role in controlling infection through bone marrow homeostasis. 
Substance P treatment has been shown to directly increase bone marrow colony 
formation in a dose dependent manner. Capsaicin, which depletes SP from nerve 
terminals, reduces overall bone marrow leukocyte counts and polarizes 
progenitors towards macrophages (15). Increased bone marrow reserves may 
contribute to the larger neutrophil influx seen with SP signaling. In severe 
infections, emergency granulopoiesis (EG) is a defense mechanism where the 
body produces and releases high levels of neutrophils through increased myeloid 
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precursor proliferation. EG is activated by PAMP interactions with TLR4 to induce 
high quantities of G-CSF that causes neutrophil precursor proliferation and 
neutrophil egress to free up space inside the marrow (127). Kwak et al. recently 
showed that EG is regulated by reactive oxygen species (ROS). Using mice with 
defects in the NADPH oxidase system, no proliferation was stimulated in severe 
infection. ROS scavenger treatment blocked EG, supporting those results. They 
were able to show by bone marrow transplantation that de novo production of 
progenitors is modulated by ROS paracrine signaling. Then, by laser scanning 
cytometry of the marrow, it was confirmed that progenitor cells are all located in 
close proximity to more mature myeloid cells that can produce ROS (110). Taken 
together, the organization of progenitors adjacent to mature myeloid cells 
supports a local paracrine signaling model of ROS-dependent EG. Earlier work in 
human peripheral blood neutrophils, demonstrated that SP increases formation 
of NO and H2O2, which was shown by Kwak to induce EG (178). Although in our 
triple labeled bacteria assay, neutrophils showed no change in ROS production, 
the assay measures only intraphagosomal ROS. Primed formation of ROS by SP 
signaling could enhance EG following severe infection that would contribute to 
heightened influx into the lungs in our model.  
 
The NK1R experiments showed that SP enhances innate immunity 
through improved neutrophil recruitment and bacterial killing. Neutrophil 
recruitment can be increased by SP signaling through increased chemokine 
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receptor expression or increased calcium flux (47). Our work in chapter 3 shows 
no difference in CXCR2 receptor expression in sham compared to mTBI mice 
and no changes with either NK-1R agonist or antagonist treatment 
experimentation. Increased neutrophil recruitment in the absence of changes in 
receptor expression may be explained by enhanced calcium flux seen in SP 
primed neutrophils (47). Calcium flux controls multiple aspects of neutrophil 
function, such as recruitment and phagocytosis. New techniques using light 
sheet microscopy can capture live images of calcium flux at the leading edge of 
recruited neutrophils and at the point of phagocytosis (5). Enhanced calcium flux 
may explain the increase in neutrophil recruitment. In addition, the triple label 
bacterial uptake assay showed a trend of increased bacterial uptake per 
neutrophil from mTBI mice. Further exploration into the biological impact of an 
improvement in phagocytosis, if multiplied across the significantly higher influx of 
PMN, may reveal a second mechanism acting in concert with NET formation. 
Further investigation into the specific mechanism of enhanced NET formation 
may offer further insights. Recent work showed that NET formation requires both 
intracellular and extracellular Ca2+ flux. Neutrophils produce NETs when 
stimulated with IL-8, but in calcium free conditions using BAPTA or TMB-8 
(intracellular chelators) or EGTA (extracellular chelator), production is greatly 
reduced. Furthermore, downstream inhibition of calcineurin using cyclosporine A 
blocks NETosis (72). As SP enhances neutrophil calcium flux to IL-8 treatment, 
these findings support our findings that NET formation is enhanced by SP (47). 
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SP primed calcium flux may in fact explain all three enhanced activities of mTBI 
neutrophils.  
 
NETosis – suicidal or vital? 
As our work shows enhanced NET formation from PMNs isolated from 
mTBI mice, is it important to note that two different pathways for NET formation 
have been described: classical and vital NETosis. Work by Yousefi et al. first 
described release of mitochondria DNA in viable neutrophils. Using GM-CSF and 
complement C5a, NETs were stimulated for 20 minutes and DNA was measured 
by fluorescence intensity. In this case, DPI, an inhibitor of NADPH oxidase 
blocked the formation of NETs (215). However, later work by Pilsczek et al. 
described a “vital NETosis” similar to Yousefi’s work. S. aureus challenge 
induced rapid formation of NETs. Instead of the lytic expulsion of DNA seen in 
classical NETosis, electron microscopy showed vesicles containing DNA being 
released into the extracellular space. This early NET formation was uninhibited 
by DPI. This earlier NET formation differed from classical NETosis by reduced 
neutrophil elastase activity (150). These two pathways of NETosis were 
confirmed by Rochael et al using a Leishmania parasite induced NETs. After 60 
min of stimulation, neutrophils produced NETs blocked by either DPI or L-NAME, 
an inducible nitric oxide synthase (iNOS) inhibitor. However, 10 min of 
stimulation produced rapid formation of NETs that was uninhibited by blockers of 
ROS generation. Most importantly, rapid and classic NETosis were equally toxic 
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in an assay of parasite killing. (160). Our current measurements of NETosis at 60 
min appear to measure the classical formation of NETs. Given that evidence 
exists for SP to prime calcium flux or ROS formation (47, 178), either pathway 
could be enhanced and should be investigated. This is of particular interest as 
Yipp et al. showed the ability of neutrophils to multitask: neutrophils undergoing 
earlier NETosis could actively phagocytose live bacteria. Using spinning-disk 
confocal microscopy combined with in vivo infection of S. aureus expressing 
fluorescent proteins, they characterized neutrophil nuclei as normal, diffuse, or 
absent. Neutrophils with diffuse nuclei, indicating formation of NETs, 
phagocytosed bacteria at similar rates to those with normal nuclei. Neutrophils 
with absent nuclei did not show any phagocytic activity (213). A recently 
published method by Zhao et al described a novel method for discerning 
between classic, now known as suicidal, and rapid, vital NETosis using 
multispectral imaging flow cytometry (MIFC). MIFC joins image capture of 
fluorescence microscopy and unbiased, rapid analysis of flow cytometry. Suicidal 
NETs were shown to have decondensed nuclei, with spherical morphology, and 
a colocalization with MPO. These features are consistent with past results that 
classical NETosis requires the ROS generation and results in cell death. 
Neutrophils undergoing vital NETosis had polarized blebs with condensed DNA 
and no MPO colocalization, reproducing earlier descriptions by Yipp that these 
vital NETs are active and can crawl towards stimuli (217). These data indicate 
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that the kinetics and composition of the enhanced NET formation may factor in 
the antimicrobial efficacy.   
 As noted above, expansion into various strains and organisms should be 
tested in our model. Even within different strains of Pseudomonas, Shan et al. 
described varying susceptibilities to NET killing potential. Invasive isolates were 
more susceptible to NET killing while cytotoxic strains evaded killing by releasing 
outer membrane vesicles that act as competitive antagonists for microbial 
binding (168). It is known that different bacteria express an array of factors, such 
as nucleases, to evade host defenses (193). Byrd et al. showed that NETs 
trapped Candida albicans for elimination, but requires interaction of fibronectin, a 
component of the extracellular matrix, and fungal surface β-glucan (19). NETs 
have even shown to prevent or reduce viral infections (212). These reports offer 
promising broad clinical applicability of enhanced innate immunity. Empirical 
evidence of efficacy would strengthen the significance of insights gleaned from 
our model.  
In our experiments, enhanced NET formation appears to be beneficial in 
clearing infections. However, excess formation may be deleterious and 
potentially add to autoimmunity (152). Clearance of NETs during the resolution of 
infection is therefore paramount to preventing collateral damage by augmented 
innate immunity. Interestingly, using MIFC, Zhao et al. showed that vital NETosis 
is enhanced in patients with systemic lupus erythematosus and not suicidal 
NETosis, further showing that identification of NETs and their clearance is 
  
135 
paramount (217). Macrophages are responsible for clearance of apoptotic 
neutrophils after an infection and timely NET clearance is important as their 
components are highly toxic or immunogenic to bystander cells. In one study, 
vagal stimulation of α4β2 nAChR was able to increase macrophage phagocytosis 
and endocytosis of particles (195). Concomitant activation of neurokinin and 
cholinergic pathways could intersect in the resolution of infection. SP signaling 
enhanced NET formation sequesters and clears the infection, then macrophages 
phagocytose the remnants with improved activity through α4β2 receptor activity. 
In chapter 3, NK1R agonist treatment enhances bacterial clearance but ultimately 
does not improve survival. It is likely that increased neutrophil number and NET 
formation leaves remnants that cause damage. Based on the evidence that both 
pathways are active, this interplay may be critical in order to completely replicate 
the mTBI resilience in pneumonia.  
 
Cholinergic Modulation of Pro-inflammatory Mediators 
The mechanism behind increased cholinergic anti-inflammatory 
modulation also requires further work. Currently, we propose that mTBI activates 
the inflammatory reflex to decrease production of damaging pro-inflammatory 
factors. Replacement of the TNFα found in mTBI or α7 agonist treated mice did 
not have an effect of survival. HMGB1 levels 24h following pneumonia were 
detectable only in sham injured mice. Work using cholinergic anti-inflammatory 
pathway agonists has shown decreased HMGB1 levels that reduces mortality in 
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models of sepsis (148). Previous work has shown that TNFα can partially drive 
release of HMGB1 by macrophages (29). HMGB1 has been reported to reduce 
barrier integrity by signaling through the receptor for advanced glycation end-
products (RAGE). On air-liquid cultures mimicking the aiway epithelium, HMGB1 
increased permeability to FITC-dextran with downregulation of occluding and 
claudin-1. This effect was potentiated by simultaneous treatment of HMGB1 with 
IL-1β (88). Ramsgaard et al showed that HMGB1-RAGE interactions were 
necessary for lung injury in an E.coli pneumonia model. RAGE-/- had significantly 
reduced lung damage after E.coli pneumonia but not after LPS challenge (155). 
Later work in a Staphyloccocus aureus pneumonia model also showed that 
HMGB1-RAGE signaling contributes to lung damage. In this model, anti-HMGB1 
antibody treatment reduced lung injury and protein leakage. In addition, specific 
RAGE signaling contributed to lung injury as RAGE-/- mice showed less lung 
pathology but TLR4-/- mice did not, similar to earlier findings by Ramsgaard (1). 
Our data suggest that TNFα is a marker, not a mediator of tissue damage. We 
propose that necrotic cells release HMGB1, but its downstream signaling to 
produce more pro-inflammatory mediators, including HMGB1, is reduced by 
cholinergic inhibition of NF-κB signaling (123). However, it remains to be seen 
whether attenuation of HMGB1 in our model is a signal of reduced tissue 
damage or a direct cause of cholinergic signaling.  
NF-κB activity has traditionally been measured as nuclear translocation or 
phosphorylation of IκBs. However, these methods do not allow for longitudinal 
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tracking. A recently published study using lentiviral insertion of a NF-κB 
luciferase reporter into alveolar macrophages allowed measurement of NF-κB 
activation throughout the duration of a pulmonary endotoxin challenge (204). 
Using this model, we may be able to see how the kinetics of NF-κB activation are 
altered and track the survival of mice during the infection period. Furthermore, 
transformed bacteria with near-infrared probes could allow for simultaneous in 
vivo imaging of bacterial load and NF-κB activity (169). We hypothesize that α7 
nAChR activation by GTS-21 or mTBI through cholinergic signaling will diminish 
NF-κB activation by alveolar macrophages. However, this system would not allow 
us to see activation in neutrophils, as it has been shown that they express α7 
nAChR on their surface (180). With some caveats, this system would allow us to 
investigate whether NF-κB repression by cholinergic signaling improves survival.  
 
Future Work 
The overarching goal of this model is to find insights into boosting innate 
immunity. Further work in our murine models should test full recapitulation of 
both pathways seen in mTBI mice. Clinical studies adding adjunct corticosteroid 
therapy to standard of care antibiotics showed improved survival (8). The results 
of this study may be taken as a proof-of-concept for replicating both pathways in 
patients. A second focus should be clinical relevance, such as testing these 
regimens in the period after pneumonia instead of prophylactic treatment. For 
example, α7 agonist and NK-1R agonist dosing after the induction of pneumonia 
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should be considered to define a therapeutic window as many patients will 
present with an infection. Furthermore, application in patients may require proper 
stratification of whether they require immune boosting or tissue protection, or a 
balance between the two. Our agonist experiments have focused on mimicking 
the signaling, but optimizing the regimen to improve outcomes should be the next 
goal. Our tail trauma model should provide a more accurate control to study 
neuroimmune priming of resistance to pneumonia.  
Administration of SP, as it has widespread effects, might be need to be 
more specifically targeted as sudden vasodilation or pro-inflammatory cytokine 
production may become deleterious. Data with ACE inhibitors or nicergoline has 
both been shown to increase serum SP levels correlated with decreased 
pneumonia risk, thus the preventing breakdown may prove superior in patients 
(120, 140). New developments in targeting drugs to preferred sites of action may 
broaden the options for treatments. As we have proposed multiple effects of SP 
on the bone marrow while signaling in the periphery may induce unwanted 
effects, bone marrow targeted liposomes may facilitate specific delivery. 
Liposome specific uptake in the bone marrow is thought to be dependent on an 
active process by resident macrophages. However, experiments in mice have so 
far not shown high specificity for the marrow, but in rabbits and rhesus monkeys, 
the liposomes are highly specific (176). This delivery method might be especially 
effective in chemotherapy patients, who are known to be immunosuppressed, 
that are taking NK1R antagonist aprepitant. A meta-analysis of trials with NK1R 
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antagonist aprepitant suggested that there may be an increased risk of serious 
infection with use of this drug in chemotherapy patients. (51). Three randomized 
controlled trials showed aprepitant treatment tripled the incidence of severe 
infection from 2 to 6% (P<0.001). High concentration of SP or targeted high 
affinity ligands may be able to displace aprepitant from NK1R in the bone marrow 
and reestablish normal immunity.  
This work shows that mTBI specifically enhances innate immune 
responses to a bacterial pneumonia challenge. Both neurokinin and cholinergic 
signaling are active following mTBI leading to synergistic effects to improve 
outcomes. SP signaling through NK1R enhances neutrophil functions: 
recruitment, killing, and NET formation. Further experimentation into phagocytic 
cell improvement should examine NET formation and whether it applies to other 
microbial infections. Primed calcium flux into neutrophils following stimulation 
could account for several of these effects, as has been shown in previous work 
by SP. Cholinergic signaling dampens inflammation. Data point towards HMGB1 
as a key mediator that is downregulated by α7 nAChR signaling. This work 
shows that future investigation into both neurokinin and cholinergic pathways 
should provide insights into optimizing innate immune responses.  
.
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